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ABSTRAK 
 
Tajuk 
 
Kajian 24-Jam Fluktuasi Tekanan Mata dalam Glaukoma Primer Sudut Tertutup 
Maju dan Tidak Maju 
 
Pendahuluan 
 
Glaukoma Primer Sudut Tertutup (GPST) merupakan penyakit yang kerap 
didiagnosa di kalangan populasi Asia. Bangsa Melayu adalah antara kaum yang 
dikenalpasti menghidapi GPST dengan prevalens sebanyak 0.12% hingga 2.5%. 
Sehingga kini, tekanan mata adalah satu-satunya risiko faktor yang boleh dikawal. 
Dua subkomponen tekanan mata iaitu purata nilai tekanan mata yang tinggi dan nilai 
jurang turun naik tekanan mata yang luas merupakan faktor penting penyebab 
kemajuan GPST. 
 
Objektif 
 
Mengenalpasti dan membandingkan purata nilai purata tekanan mata, nilai puncak, 
nilai dasar, dan nilai turun naik dalam masa 24 jam, di kalangan mata GPST maju 
dan tidak maju.   
 
 
 
 xi 
Metodologi 
 
Satu kajian keratan rentas telah dijalankan di Hospital Universiti Sains Malaysia, 
Kelantan yang mana melibatkan seramai 25 pesakit dengan 50 mata yang telah 
didiagnosa GPST. Mereka dibahagikan kepada 2 kumpulan iaitu mata maju dan mata 
tidak maju. Kesemua mereka dimasukkan ke dalam wad selama 24 jam. Tekanan 
mata diukur sebanyak 6 kali selang masa 4 jam, iaitu pada 0800, 1200, 1600, 2000, 
2400, dan 0400. Tonometer Aplanasi Goldmann digunakan untuk semua pengukuran 
tekanan mata.  Analisis statistik yang digunakan adalah ujian ‘independent t’, ujian 
‘Mann-Whitney U’, dan ujian ‘Fisher’s exact’. 
 
Keputusan 
 
Keputusan kajian mendapati bahawa majoriti dari kumpulan mata GPST maju 
menunjukkan nilai tekanan mata puncak pada sebelah malam dengan nilai tekanan 
mata dasar pada sebelah petang, manakala kumpulan mata tidak maju menunjukkan 
nilai tekanan mata puncak pada sebelah pagi dan nilai tekanan mata dasar pada 
sebelah malam. Pada selang masa 4 jam, kumpulan mata maju mempunyai nilai 
purata tekanan mata, nilai puncak, dan nilai dasar yang lebih rendah tetapi jurang 
nilai turun naik yang lebih luas. Dalam masa 24 jam, tiada perbezaan yang signifikan 
pada semua variasi tekanan mata. Keseluruhannya, julat nilai purata tekanan mata  
adalah antara 13.7 ke 15.3 mmHg (p = 0.202), julat nilai purata tekanan mata puncak 
adalah antara 17.0 ke 18.0 mmHg (p = 0.285), julat nilai purata tekanan mata dasar 
adalah antara 11.0 ke 13.0 mmHg (p = 0.151), dan julat nilai turun naik tekanan mata 
adalah 6.0 mmHg (p = 0.803). 
 xii 
Kesimpulan 
 
Hasil kajian menunjukkan tiada perbezaan yang signifikan pada semua variasi 
tekanan mata dalam masa 24 jam dalam kedua-dua kumpulan mata GPST maju dan 
tidak maju. Walaupun julat nilai turun naik tekanan mata adalah sama dalam masa 24 
jam, kumpulan mata maju menunjukkan jurang nilai turun naik tekanan mata yang 
lebih luas pada selang masa 4 jam.  
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ABSTRACT 
 
Title 
 
The Effect of 24-Hour Intraocular Pressure Fluctuation on Glaucoma Progression in 
Primary Angle Closure Glaucoma 
 
Introduction 
 
Primary Angle Closure Glaucoma (PACG) is a common glaucoma type in Asian 
population. Malays are among affected races in South East Asian with PACG 
prevalence of 0.12% to 2.5%. To date, intraocular pressure (IOP) is the only 
modifiable glaucoma risk factor. Two IOP subcomponents; the higher mean IOP and 
the wider IOP fluctuations are currently being looked upon as important predictors of 
glaucoma progression.  
 
Objectives 
 
To determine and compare the 24-hour overall mean IOP, mean IOP peak, mean IOP 
trough, and IOP fluctuation in progressed and non-progressed PACG.    
 
 
 
 
 
 xiv 
Methodology 
 
A cross-sectional study was conducted in Hospital Universiti Sains Malaysia, 
Kelantan involving 25 patients with 50 eyes diagnosed with PACG. They were 
grouped into progressed PACG (11 eyes) and non-progressed PACG (39 eyes). 
AGIS scoring system was used to determine the progression group. All patients were 
admitted for 24 hours period. Six IOP measurements were performed at 4-hour time 
points; at 0800, 1200, 1600, 2000, 2400, and 0400.  Goldmann Applanation 
Tonometer (GAT) was used for all IOP measurements. Statistical analysis used were 
independent t test, Mann-Whitney U test, and Fisher’s exact test. 
 
Results 
 
Majority of progressed eye group of PACG exhibited patterns of night peak with 
afternoon trough, while non-progressed eye group showed patterns of morning peak 
with night trough. At 4-hour time points, the progressed eye group had lower mean 
IOP, mean peak IOP, and mean trough IOP but wider mean IOP fluctuation.  Over 
24 hour period, there was no significant difference for all IOP variables in both 
groups. The 24-hour mean overall IOP mean range was 13.7 to 15.3 mmHg (p = 
0.202), overall mean IOP peak range was 17.0 to 18.0 mmHg    (p = 0.285), overall 
mean trough range was 11.0 to 13.0 mmHg (p = 0.151), and overall mean IOP 
fluctuation was 6.0 mmHg (p = 0.803). 
 
 
 
 xv 
Conclusion 
 
Progressed and non-progressed eye group of PACG demonstrated no significant 
difference in terms of all IOP variables over 24-hour period. Despite similar overall 
mean IOP fluctuation during 24-hour period, the progressed eye group had wider 
mean IOP fluctuation than the non-progressed eye group at 4-hour time points.                    
 xvi 
                  
 
CHAPTER 1 
INTRODUCTION           
 II 
 1.0 INTRODUCTION 
 
1.1 Glaucoma 
 
Glaucoma is a progressive optic neuropathy disease with blinding potential. It 
commonly refers to a group of disorders that exhibit optic nerve head cupping and 
characteristic visual field loss. Glaucoma in Greek means clouded or blue-green hue, 
which Hippocrates first used to describe blindness in advanced years associated with 
pupil’s glazed appearance (Fronimopoulos & Lascaratos, 1991). 
 
The understanding of pathogenesis of glaucoma involves 2 theories; mechanical and 
vascular mechanism. These 2 concepts were introduced in mid-nineteenth century. 
Muller suggested the mechanical theory in 1858, while von Jeager proposed the 
vascular theory in the same year (Pinazo-Duran et al., 2011). Elevated IOP is 
responsible for optic nerve compression and death of the neurons in the mechanical 
mechanism, where as vascular dysregulation affecting ocular perfusion pressure that 
leads to optic atrophy is postulated to play the main role in the vascular mechanism. 
Both eventually share common final sequel: progressive visual field defect hence 
blindness.  
 
Global impact of glaucoma is devastating. It is costly from both human and 
economic perspectives. Glaucoma affects quality of vision as well as quality of life. 
WHO demonstrated that approximately 5.2 million blindness attributable to 
glaucoma, which represented 15% of total burden of world blindness (Thylefors and 
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Negrel, 1994). In Malaysia, glaucoma emerged as the fifth leading cause of blindness 
and low vision according to National Eye Survey 1996  (Zainal et al., 2002). Local 
survey showed that it was the second leading cause of blindness in urban population 
after cataract (Reddy et al., 2008). In other South East Asia countries, glaucoma is 
the second cause of blindness in China, Thailand and Singapore, and the third cause 
of blindness in Philippines (Rojanapongpun, 2005).  
 
Visual impairment secondary to glaucoma may cause difficulties in mobility, driving 
and social interactions (Coleman, 1999). Glaucoma patients are also likely at higher 
risk to involve in motor vehicle collision owing to their restricted visual field 
(McGwin et al., 2005). Blind glaucoma patients are dependent of activity daily 
living, thus contribute further to burden people around them, especially the family 
and relatives. In terms of nation economic burden, cost effectiveness on medications 
and surgeries is among the issues apart from expenditures spent on regular visits 
monitoring and compliance, screening and investigation tools purchases, and losing 
human resource from blindness.  
 
WHO has classified glaucoma into 3 groups: congenital (genetic or development), 
primary glaucoma (open angle or angle closure), and secondary glaucoma. All these 
have different etiologies and course of treatment. Worldwide, the distribution of 
PACG and POAG is both geographically and ethnically variable. PACG is common 
in Asia, while POAG predominates in other parts of continents. PACG was estimated 
to blind more people than POAG (Foster et al., 2000).  
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Despite the alarming figures of glaucoma cases observed each year, the vision loss 
usually can be delayed with early detection and appropriate management. Factors 
influencing the increase in glaucoma prevalence are varied and not been fully 
understood. Among these, IOP remains the most prominent and consistent glaucoma 
risk factor as concluded by 4 major studies: Ocular Hypertension Treatment Study 
(OHTS), Early Manifest Glaucoma Trial (EMGT), Advanced Glaucoma Intervention 
Study (AGIS), and Collaborative Normal Tension Glaucoma Study (CNTG) 
(Coleman et al., 2004; Bengtsson et al., 2007; Caprioli & Coleman, 2008; Anderson, 
2003). 
 
As it is the only modifiable risk factor, lowering IOP has been a mainstay focus of 
glaucoma treatment, either by pharmacologically, or surgically, or both. The results 
of the AGIS have proven that lowering IOP prevents further optic nerve damage by 
maintaining targeted average IOP 12-14 mmHg, as signified by no visual field 
progression over the 7 years course compared to those who had higher IOP. But 
keeping IOP at low level is just inadequate. There is other issue beyond the target 
IOP level to answer why many patients still progress despite achieved target IOP at 
intervisits. The idea of “IOP stability” concept hence was introduced and frequently 
emphasized in current studies.  Two IOP subcomponent; the mean IOP and IOP 
fluctuations are now being looked upon as another important predictors of glaucoma 
progression. Therefore, stabilizing both parameters need to be included and tailored 
in the management strategy (Asrani et al., 2000; Singh & Shrivastava, 2009).  
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1.2 Angle Closure Glaucoma 
 
1.2.1 Epidemiology of Angle Closure Glaucoma 
 
WHO data in 1993 shows that about 23 million individuals had confirmed glaucoma 
while glaucoma suspects reached around 105 million persons. Out of this figure, 
POAG affects 13.5 million cases and PACG accounts for 6 million people, both seen 
in subjects over age 40 (Thylefors & Negrel, 1994). The prevalence of glaucoma is 
increasing and by year 2020, an estimated 79.6 million people worldwide are 
expected to develop glaucoma (Quigley & Broman, 2006).  Population-based data 
from South East Asia Glaucoma Interest Group Meeting (SEAGIG 2004) showed 
POAG has higher rate than PACG in Malaysia, Singapore and Thailand, with reverse 
order for Philippines (Rojanapongpun, 2005). However data for PACG in Asia have 
increased in past few years (See et al., 2011). Cedrone and colleague analyzed a 
series of 56 studies on glaucoma prevalence, and concluded that PACG is 
commonest among Asian ethnic groups whereas POAG is more common in African 
origin and white population  (Cedrone et al., 2008). In Malaysia, ratio of POAG to 
PACG was approximately 1.5:1.0 (Rojanapongpun, 2005). Prevalence of PACG in 
adult Asians was 0.75% and more than half of them were female (Cheng et al., 
2014). It increases with age (Foster et al., 2000).  Malays are among affected races in 
South East Asian with PACG prevalence of 0.12% to 2.5% (Shen et al., 2009; 
Bourne et al., 2003; Casson et al., 2007). In a hospital-based study in Malaysia, the 
prevalence of PACG was once reported 30.0% and the incidence of PACG was once 
reported 0.86% with Malays accounted one third of the 3 major races (Selvarajah, 
1998).  
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1.2.2 Classification of Angle Closure  
 
According to International Society Geographical & Epidemiological Ophthalmology 
definition, glaucoma with angle closure is classified and staged into Primary Angle 
Closure Suspect (PACS), Primary Angle Closure (PAC), and Primary Angle Closure 
Glaucoma (PACG). In PACS, narrow angle is the only abnormality present. It may 
progress to PAC with manifested high IOP and other findings, but without 
glaucomatous optic disc changes. PACG hence, reserved for PAC in presence of 
glaucomatous optic neuropathy with or without visual field loss (Foster et al., 2002). 
 
1.2.3 Mechanism of Angle Closure 
 
There are 4 main mechanisms of angle closure, each of which may co-exist with 
another: pupil-block (block at level of iris), anterior non pupil-block that includes 
plateau iris (block at level of ciliary body), lens-related (block at level of lens), and 
retrolenticular (block posterior to lens) (Ritch & Lowe, 1996). Identifying 
mechanism responsible for angle closure is important in addition to establish the 
disease stage. It is helpful in guiding the appropriate choice of treatment. The two 
schemes (staging and mechanism) therefore should be used in parallel when 
managing an angle closure case. 
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1.2.3.1   Assessment of anterior chamber depth 
 
Anterior chamber depth can be assessed qualitatively using Smith’s method and Van 
Herrick’s method. Both use slit lamp biomicroscope. Smith’s method estimates the 
central anterior chamber depth, while Van Herrick’s method approximates the 
peripheral (Smith, 1979; Van Herick et al., 1969). Another method of assessment is 
by using A-scan, which is quantitative.  
 
1.2.3.2   Assessment of anterior chamber angle 
 
Gonioscopy is the commonest procedure in assessing anterior chamber angle. It uses 
contact goniolens together with slit lamp biomicroscope. The angle was subsequently 
graded using Shaffer system, which consists of 5 grades from 0 to 4 (Fellman et al., 
2012). Apart from gonioscopy, cross-sectional images of anterior chamber structures, 
specifically the angles also can be generated using Optical Coherence Tomography 
(OCT) and Oculus Pentacam. These images can be used to take measurements of the 
angle. 
 
1.2.4 Risk factors of Angle Closure Glaucoma 
 
Assessing risk factors in a potential angle closure glaucoma patient is essential. Mass 
screening can be narrowed down to a selected population. It also aids in predicting 
the incidence of acute attack and long-term glaucoma progression. Ocular biometry 
risk factors are narrow drainage angles, shorter axial length, shallow anterior 
chamber depth, lens thickness and position, and thicker iris. Meanwhile, the systemic 
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risk factors include age of 40 years and above, female gender, ethnicity of Inuit or 
East Asian, genetic, and environmental such as climate monsoon (Ameraginghe, 
2008) (Ch’ng et al., 2013). Amongst these, shallow anterior chamber depth is the 
leading anatomical risk factor with Chinese ethnicity has the most significant 
anterior chamber and angle anatomy difference.  
 
1.2.5 Clinical Presentation of Angle Closure Glaucoma 
 
Classic acute primary angle closure (APAC) episode usually brought patient earlier 
to ophthalmologist due to intolerable eye pain and worsened vision. In such case, 
IOP reading almost always high and complicated with injected conjunctiva, 
epithelial edema, shallow anterior chamber, mid-dilated pupil, iris ischemia, and 
hazy fundal view. However, it is also not uncommon to diagnose cases of advanced 
PACG at first visit. Painless typical glaucomatous visual field loss and characteristic 
glaucomatous disc cupping are the common late signs. Nevertheless, both acute and 
chronic stages are often seen overlapping in the clinical presentation.  
 
1.2.6 Management of Angle Closure Glaucoma 
 
Diagnosis of angle closure glaucoma is mainly clinical and should be made with 
careful slit lamp examination, which include IOP measurement and gonioscopy. 
Further investigations may be required such as visual field, ultrasound 
biomicroscopy, optic nerve head analysis by optical coherence tomography, and 
central cornea thickness. The aim of treating PAC and PACG is to eliminate the 
underlying pathophysiological mechanism and to reduce IOP. This can be achieved 
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medically and/or surgically. Medical treatment consists of laser peripheral iridotomy 
or iridoplasty, and IOP lowering agents that can be delivered topically, per oral or 
intravenous. They are available from classes of beta blocker, adrenergic agonist, 
prostaglandin analog, carbonic anhydrase inhibitor, parasympathomimetic, fixed 
combination medications, and hyperosmotic agents. Surgically, options include 
trabeculectomy, lens extraction, combined lens extraction with trabeculectomy, and 
glaucoma drainage device implantation (See et al., 2011). In case of acute PAC, 
rapid IOP reduction and control is needed to limit optic nerve insult, hence 
preventing long-term glaucoma progression. 
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1.3 Intraocular Pressure 
 
1.3.1 Concept of Normal Intraocular Pressure 
 
Intraocular pressure is determined by balance between aqueous production and 
outflow. Goldmann equation clearly described the relationship between the IOP and 
the components of aqueous humor dynamics: Po = (F/C) + Pv ; Po is the IOP in 
millimeters of mercury (mmHg), F is the rate of aqueous formation, C is the facility 
of outflow, and Pv is the episcleral venous pressure (American Aceademy of 
Ophthalmology, 2011). Mean IOP of 15.5 mmHg, with a standard deviation of 2.6 
mmHg have been reported in large-scale population-based epidemiologic studies. 
Therefore “normal” IOP is defined as 2 standard deviations above or below the mean 
IOP, or approximately 10-21 mmHg. IOP of outside this range is considered 
pathological and abnormal (Alimuddin, 1956). 
 
1.3.1.1   Aqueous humour formation 
 
There are two steps of aqueous humour production. Firstly, plasma filtrate is formed 
within the stroma of ciliary body. Secondly, aqueous humour is formed from this 
filtrate across the blood-aqueous barrier. The aqueous humour subsequently secreted 
into posterior chamber through two mechanisms, in which active secretion 
predominates than passive secretion. Active secretion by non-pigmented ciliary 
epithelium involves metabolic process that is Na+/K+ ATPase pump dependent, 
whereas passive secretion by ultrafiltration and diffusion are dependent on capillary 
hydrostatic pressure, oncotic pressure and IOP level (Kanski & Bowling, 2011) 
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1.3.1.2   Aqueous humour outflow 
 
Aqueous humour flows from the posterior chamber into the anterior chamber via 
pupil. From there, it exits the eye by two different routes, either through trabecular or 
uveoscleral. Trabecular route is also known as conventional route as it accounts for 
approximately 90% of aqueous outflow. From trabecular, aqueous humour then 
enters Schlemm canal and is subsequently drained by episcleral veins. The remaining 
10% will be channeled into uveoscleral route (Kanski & Bowling, 2011). 
 
1.3.2 Measurement of Intraocular Pressure 
 
IOP in general, is indirectly calculated by measuring the amount of force that is 
required to flatten a section of cornea. Various IOP measurement tools have been 
developed over decades. Basically, there are 4 types of tonometry available to date: 
applanation tonometry (Goldmann tonometry, Perkins tonometry, Ocular Response 
Analyzer, air puff tonometry), indentation tonometry (Schiotz tonometer, 
Pneumotonometer, Tono-Pen), rebound tonometry (ICare), and Pascal Dynamic 
Contour Tonometer. Amongst these, Goldmann applanation tonometry remains a 
gold standard in IOP taking, despite its shortage on numerous ocular biomechanical 
factors that can erroneously lead to overestimation or underestimation of IOP 
measurement. Furthermore, it is known that repeated applanation testing using 
Goldmann-type tonometers might decrease IOP in ipsilateral eye, which cannot fully 
be explained (Moses, 1961). With emergence of newer inventions, IOP 
measurements are no longer affected by ocular biomechanical properties that are 
significant in Goldmann tonometry measurement. Recent development of more 
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advanced invention using contact lens sensor (SENSIMED Triggerfish), allows 
short-term reproducibility of continuous 24-hour IOP monitoring (Mansouri et al., 
2012). Studies on this device are currently on going in evaluating its clinical safety, 
tolerability and efficacy.   
 
1.3.3 Factors Affecting Intraocular Pressure Measurement Accuracy 
 
IOP measurements in clinical setting may be affected by numerous ocular 
biomechanical factors of cornea and tear film such as central cornea thickness, 
cornea curvature, corneal rigidity and hydration, cornea scarring, thin or thick of tear 
film (Whitacre & Stein, 1993). False elevated IOP reading may be contributed 
mechanically such as pressure from a finger on the eyelid while taking the 
measurement, in squeezed eyes, breath holding and Valsalva maneuver by the patient 
during measurement. The choice of IOP measurement tools hence needs 
consideration in different situations. 
 
1.3.4 Goldmann Applanation Tonometer 
 
Goldmann Applanation Tonometer (GAT) is the gold standard of IOP measurement. 
It requires fluorescein dye to highlight tear film. The force of flattening cornea area 
of 3.06 mm diameter is measured. The tonometer uses split-imaged prism that 
generates image of tear meniscus, which divides into superior and inferior arc. When 
both arcs are aligned in such that their inner margins just touch, IOP is taken. As 
wide contact surface area is needed for the measurement with fluorescein dye, local 
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anesthetic eye drop is essential for patient’s comfort. GAT needs calibration at 
frequent interval.  
 
1.3.5 Intraocular Pressure Circadian Rhythm in Primary Angle Closure Glaucoma 
 
Many agreed that IOP fluctuate in rhythmical circadian pattern and eyes with 
glaucoma were observed to have greater fluctuation. Circadian rhythm of IOP 
comprises the diurnal and nocturnal curves. Pattern of IOP diurnal curve varies in 
different types of glaucoma (Wilensky, 1991). IOP circadian rhythm in PACG has 
been compared to POAG and normal eyes over 24-hour period in few studies. In 
PACG, documented average IOP peak was 25 mmHg, range of IOP was 12-32 
mmHg, and diurnal fluctuation was 6-8 mmHg (Sihota et al., 2005). The 3 
parameters did not significantly differ when comparing PACG to POAG, however 
significant lower values were observed in normal eyes. In PACG and PAC eyes, 
higher diurnal IOP fluctuation of 4-5 mmHg has been observed in comparison to 
PACS patients and normal controls (Baskaran et al., 2009). In PACG, IOP peak was 
observed not only in afternoon, but also at night or early morning, midnight and 
morning (Sihota et al, 2005; Leydhecker, 1976; Shapiro & Zauberman, 1979). 
Greater IOP dependence was observed for optic nerve damage in PACG than POAG 
(Gazzard et al., 2003). A diurnal fluctuation of more than 6 mmHg with IOP 21 
mmHg was never seen in normal eyes and should be considered pathological if 
present.  
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1.3.6 Factors Affecting Intraocular Pressure Fluctuation 
 
IOP physiologically is in a state of flux and therefore it varies in short and long term 
(Kirstein et al., 2011). There are many factors affecting physiological IOP, and this 
may exaggerate in glaucoma individuals. Diurnal variation is one of many other 
factors contributing to short-term fluctuations, apart from body posture, exercise, eye 
movements, Valsalva maneuvers and various food or drugs consumption. IOP has 
been observed to have nocturnal variation (Liu, 1998) and most IOP peaks occur 
outside office hours (Mosaed, 2005). Postural changes have significant effect on IOP 
(Bill, 1978; Baskaran et al., 2006). On the other hand, long-term fluctuations have 
been associated with advanced age, season, diet, systemic blood pressure, race, 
ethnic origin, and body weight. Persistent accumulative short-term variation may 
lead to long-term fluctuation. It is believed that long-term fluctuation of IOP may be 
a risk factor for glaucoma progression (Bergea et al., 1999; Asrani et al., 2000; 
Nouri-Madhavi et al., 2004). 
 
1.3.7 Role of Intraocular Pressure Fluctuation in Glaucoma Progression 
 
At present, recent data suggests that there are more risk factors to consider in 
glaucoma rather than IOP measurement taken in clinic during office-hour visit. 
Being an inconstant value, IOP varies considerably and respond to short as well as 
long-term influences. Despite that, a pattern to IOP variation over 24 hours course 
seems to be observed in which a given individual has reasonable amount of 
consistency and reproducibility (Wilensky, 1991). Other diurnal variation in the 
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body, such as cortisol production, was thought to be related to this pattern (Schwartz, 
1966).  
 
Role of 24-hour IOP, thus control plays an important aspect in glaucoma 
management. Its implication as a risk for progression demonstrated by fluctuation as 
observed in many published studies. IOP fluctuations have been shown to increase 
risk of visual field progression in treated eyes (Asrani et al., 2000). AGIS reported 
that over 7 years, IOP fluctuation of 1 mm Hg increased risk of progression by 30% 
(Nouri-Mahdavi et al., 2004).   Diurnal and nocturnal IOP measured in habitual 
position provide new insights, although accuracy of measurement technique made is 
questionable. Treatments have different effects on diurnal and nocturnal IOP. Newest 
class of glaucoma medications; the prostaglandin analogues, claimed medically 
lower the IOP, and stabilize the IOP circadian rhythm at the same time. Studies on 
24-hour and nocturnal efficacy of glaucoma medications are ongoing (Orzalesi et al., 
2000; Liu et al., 1999; Sit et al., 2006; Liu et al., 2005). Current 24-hour IOP 
monitoring in sleep laboratory is a research tool. Clinical practical 24-hour 
monitoring of IOP could increase our ability to understand glaucoma progression and 
its treatment effects. 
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1.3.8 Monitoring of Intraocular Pressure Fluctuation 
 
There are several indications where 24-hour IOP measurement should be evaluated: 
in glaucomatous patients with progressive damage whenever single IOP reading is 
within ‘normal’ range; in patients with ocular hypertension where baseline IOP 
levels is required to monitor the condition; and in cases where incidental suspicious 
glaucomatous disc without apparent IOP elevation (David et al., 1992).  
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1.4 Rationale Of Study 
 
Glaucoma is an unpreventable disease of occurrence, whereby management is aimed 
to delay and retard its progression. As IOP is the known modifiable risk factor, 
reducing it has become our mainstay focus of treatment. Wide IOP fluctuation has 
been demonstrated to be a risk of glaucoma progression. Hence it is essential to 
determine and compare pattern of 24-hour IOP fluctuation in PACG patients in our 
local population thus its effect on visual field progression within both groups.  This 
study hopefully will provide an insight on strategizing an aggressive target on 
lowering mean intraocular pressure, thus potentially minimize and narrow the 
intraocular fluctuation at identified specific hour.  
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 2.0 STUDY OBJECTIVES 
 
2.1 General Objectives Of This Study 
 
To study the pattern of 24-hour intraocular pressure fluctuation in primary 
angle closure glaucoma patients. 
 
2.2 Specific Objectives Of This Study 
  1. To determine the 24-hour overall mean intraocular pressure, overall 
intraocular pressure mean peak, overall intraocular pressure mean trough, 
and overall intraocular pressure fluctuation in progressed eye group of 
PACG  
 2. To determine the 24-hour overall mean intraocular pressure, overall 
intraocular pressure mean peak, overall intraocular pressure mean trough, 
and overall intraocular pressure fluctuation in non-progressed eye group 
of PACG  
 3. To compare the 24-hour overall mean intraocular pressure, overall 
intraocular pressure mean peak, overall intraocular pressure mean trough, 
and overall intraocular pressure fluctuation between progressed and     
non-progressed eye group of PACG  
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 3.0 METHODOLOGY 
 
3.1 Study Design 
 
This is a comparative cross sectional study. 
 
3.2 Research Setting 
 
3.2.1 Study Research Population: Patients diagnosed with PACG, attending regular 
visits in Ophthalmology Clinic, Hospital Universiti Sains Malaysia 
 
3.2.2 Period of Study : May 2012 till May 2014 
 
3.2.3 Place of Study : 1. Ophthalmology Clinic, Hospital Universiti Sains Malaysia 
      2. Ophthalmology Ward, 2 Utara, Hospital Universiti Sains  
                                           Malaysia 
 
3.3 Sampling And Sample Size 
 
3.3.1 Sampling Method  
 
PACG patients in HUSM who fulfilled inclusion criteria and consented to participate 
in the study were recruited. 
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3.3.2 Sample Size 
 
Sample size was calculated using PS (“Power and Sample Size”) software, version 
3.0.43 . t-test formula with independent design was applied. 
 
α : level of significance 
SD or σ : standard deviation of mean IOP 
DD or δ = the smallest, clinically meaningful difference in mean IOP that is desired 
to be detected 
m : ratio between progress and stable  
n : sample size 
  
α = 0.05  
Power of study = 0.8 
SD or σ = 1.24 (reference: Baskaran et al., 2009) 
DD or δ = 1. 0  
m = 1 
n = 25  
n + 10% (expected dropout) = 25 + 3 
Total of 28 eyes per arm are required for this study 
Total of 56 eyes are required for this study 
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3.4 Selection Criteria 
 
3.4.1 Inclusion Criteria 
i) Age more than 40 
ii) Patients with established diagnosis of PACG  
iii) At least 2 years of glaucoma clinic follow-up 
 
3.4.2 Exclusion Criteria 
i)   History of  penetrating keratoplasty  or filtering surgery 
ii)  History of cataract surgery within previous 6 months 
iii) Patients with secondary glaucoma and glaucoma suspect 
iv) Very advanced stage of glaucoma (based on AGIS score) 
v)  History of severe dry eye syndrome, recurrent corneal epithelial erosion,   
      delayed cornea wound healing, active keratitis or conjunctivitis 
            vi) BCVA 3/60 and worse 
 
3.5 Ethical Approval 
 
This study received approval from the Research Ethics Committee (Human), School of Medical Sciences, Universiti Sains Malaysia Health Campus. The research protocol 
adhered to the provision of the Declaration of Helsinki for research involving human 
subjects. 
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This study was supported by the Universiti Sains Malaysia grant. The research short 
term grant (account number 304/PPSP/61313008) was approved by Timbalan Naib 
Canselor (Penyelidikan dan Inovasi), Universiti Sains Malaysia. 
 
3.7 Definition Of Terms 
 
3.7.1 Primary Angle Closure Suspect (PACS) 
 
PACS is the initial event that may progress to PAC and subsequently to PACG. 
There is narrow angle, in the absence of other abnormality. Narrow angle is 
evidenced on indentation gonioscopy by inability to see posterior (pigmented) 
trabecular meshwork angled 1800 to 2700, which is due to appositional contact 
between peripheral iris and the posterior trabecular meshwork (Foster et al., 2002; 
Aung, 2005). 
 
3.7.2 Primary Angle Closure (PAC) 
 
In PAC, the narrow angle is present in combination with consequence of angle 
closure process such as peripheral anterior synechiae and/or IOP rise. IOP is raised 
as a result of closure of the narrow angle, and is defined as >2 standard deviations 
above norm for studied population. Other signs that may present are iris whorling 
(distorted radially orientated iris), ‘glaucomfleken’, lens opacities, and excessive 
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pigmented trabecular meshwork. Significant optic nerve damage is absent. Patient 
can be asymptomatic or symptomatic (Foster et al., 2002; Aung, 2005). 
 
3.7.2.1 Acute Primary Angle Closure (Acute PAC) 
 
Acute PAC is symptomatic PAC in which acute episode of angle closure occurs. 
This attack may happen at any stage during the disease but leaves no detectable 
nerve damage following prompt treatment (Foster et al.,  2002; Aung, 2005). 
   
3.7.3 Primary Angle Closure Glaucoma (PACG) 
 
PACG is the final sequelae of the event. There is evidence of glaucomatous optic 
neuropathy with or without visual field loss, in combination with changes seen in 
PAC (Foster et al., 2002; Aung, 2005). 
 
3.7.4 Peripheral Anterior Synechiae (PAS) 
 
PAS is detectable on gonioscopy. It refers to adhesion of peripheral iris to the 
anterior angle structures, most commonly the functional trabecular meshwork. 
Rarely it may extend to the Schwalbe’s line. Characteristically, PAS are broad and 
irregular adhesions, bridge the angle recess, obscure the underlying structures, inhibit 
posterior movement of iris on indentation, and drag normal iris vessels with it (Nema 
& Nema, 2014). 
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3.7.5 Intraocular Pressure (IOP) 
 
IOP is defined as tension inside the eyeball. It is measured with tonometer, either 
through contact or non-contact method. Bilateral IOP can be symmetric or 
asymmetric.  IOP does fluctuate, throughout the day (short term) or over longer 
intervals (long term). Normal IOP range is between 10 to 21 mmHg (Alimuddin, 
1956). IOP above 21 mmHg is abnormal. IOP is the only modifiable risk factor 
affecting glaucoma progression (Coleman et al., 2004; Bengtsson et al., 2007; 
Caprioli & Coleman, 2008; Anderson, 2003). 
 
3.7.5.1 Mean IOP 
 
Mean IOP is defined as average of IOP readings at particular point of time or period 
(Liu et al., 1999). Mean IOP at 4-hourly interval and overall mean peak IOP during 
24-hour period has been described in details of methodology (refer 3.9.2.2). 
  
3.7.5.2 Mean Peak IOP 
 
Peak IOP is defined as maximum IOP reading during 24-hour period (Baskaran et 
al., 2009). Mean peak IOP at 4-hourly interval and overall mean peak IOP during 24-
hour period has been described in details of methodology (3.9.2.3). 
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3.7.5.3 Mean Trough IOP 
 
Trough IOP is defined as minimum IOP reading during 24-hour period (Baskaran et 
al., 2009). Mean peak IOP at 4-hourly interval and overall mean peak IOP during 24-
hour period has been described in details of methodology (refer 3.9.2.4). 
 
3.7.5.4 Mean IOP Fluctuation 
 
Overall mean IOP fluctuation is defined as the difference between the peak IOP and 
the trough IOP during 24-hour period (Baskaran et al., 2009). In this study, Mean 
IOP fluctuation at 4-hourly interval is defined as the difference between IOP values 
at each interval. IOP at each interval was calculated by subtracting lower IOP value 
from higher IOP value.   
Mean IOP fluctuation at 4-hourly interval and overall mean IOP fluctuation during 
24-hour period has been described in details of methodology (refer 3.9.2.5). 
 
3.7.6 Circadian Rhythm of IOP 
 
Circadian rhythm of IOP is defined as daily rhythmic activity cycle based on 24-hour 
period. It consists of peaks and troughs at different period of daytime (diurnal) and 
nighttime (nocturnal). 
Each eye’s circadian rhythm was classified as having one of the following 3 patterns 
of peak; morning, afternoon and night; and 3 patterns of trough; morning, afternoon, 
and night (Sihota et al., 2005).  
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3.7.6.1 Peak Pattern 
 
Peak pattern is defined as the maximum mean IOP readings at particular period of 
morning, afternoon, or night  (Sihota et al., 2005). Measurement of peak pattern has 
been described in details of methodology (refer 3.9.2.6). 
 
3.7.6.2 Trough Pattern 
 
Trough pattern is defined as the minimum mean IOP readings at particular period of 
morning, afternoon, or night  (Sihota et al., 2005). Measurement of trough pattern 
has been described in details of methodology (refer 3.9.2.6). 
 
3.7.7 Visual Field 
 
3.7.7.1 AGIS VF Score  
 
This is an objective, quantitative method of scoring test reliability and severity of 
glaucomatous field loss using Humphrey Visual Field Analyzer. It was initially 
developed and used for Advanced Glaucoma Intervention Study (AGIS 2, 1994). 
Method of Humphrey VF assessment and AGIS score has been described in details 
of methodology (refer 3.9.3.1 and 3.9.3.2). 
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3.7.7.2 Progression of VF Loss 
 
3.7.7.2.1 Progressed eye group of PACG 
 
It is defined as the first occurrence in an eye, at 3 consecutive 6-monthly visits, of 
worsening in the VF score of ≥ 4 from the baseline value; changes in the AGIS VF 
defect score are measured from pre-intervention reference values (AGIS 2, 1994). 
 
3.7.7.2.2      Non-progressed eye group of PACG 
 
It is defined as VF score of ≤ 3 from the baseline value (AGIS 2, 1994). 
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3.8 Study Instruments 
 
3.8.1 Slit Lamp Biomicroscopy 
 
The Topcon slit lamp, model Topcon SL-3F (Topcon, Japan) was used for slit lamp 
examinations. 
 
3.8.2 Goldmann Applanation Tonometer 
 
The Haag-Streit Goldmann applanation tonometer was also used to take IOP 
measurements. It was calibrated monthly with a standard tonometer calibrator. 
 
3.8.3 Goldmann Three Mirror Lens 
 
The Goldmann three mirror lens was used to assess the anterior chamber angles. 
Angles then were graded based on Shaffer classification. 
 
3.8.4 Humphrey Visual Field Analyzer 
 
The Humphrey Visual Field Analyzer II model 750i was used for subjective 
assessment of patient’s visual field. It is a type of static, automated, computerized 
perimetry. Incorporated program used was Swedish Interactive Threshold Algorithm 
Standard (SITA-Standard) strategy with 24-2 test pattern. 
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3.8.5 Eye Drops 
 
i.  Guttae Proparacaine Hydrochloride 0.5% (Alcaine) 
 
This is topical anaesthesia of rapid and short-acting type. It is preserved with 
benzalkonium chloride 0.01%. It was used to anaesthesized cornea in facilitating 
Goldmann applanation tonometry procedure and gonioscopy.  
 
ii. Guttae Tropicamide 1% (Mydriacyl) 
 
This is a topical muscarinic antagonist of short-acting type. It was used to dilate 
pupils for fundus examination specifically optic disc clinical assessment.  
 
3.8.6 Fluorescein Sodium Strip 
 
Fluorescein sodium strip (Fluorets, Chauvin) was used with guttae proparacaine 
hydrochloride 0.5% to stain cornea to facilitate IOP measurement with Goldmann 
applanation tonometer. 
 
3.8.7 90 Diopter Lens 
 
The 90D (Volk, Germany) non-contact lens was used with slit lamp for fundus 
viewing to assess optic nerve head. 
 
 
 28 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Humphrey Visual Field  
Analyzer model 750i 
Figure 3.2: Goldmann Applanation 
Tonometer mounted on slit lamp 
Figure 3.3: Gutt proparacaine 0.5%       Figure 3.4: Fluorescein sodium strip 
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3.9 Details Of Methodology 
 
3.9.1 Recruitment of Study Group 
 
Recruitment of study cases consisted of patients with established diagnosis of PACG 
and attending regular visits in Ophthalmology Clinic, Hospital Universiti Sains 
Malaysia. Basic slit lamp examination and visual acuity assessment with Snellen 
chart was performed prior to enrollment. Patients were screened for inclusion and 
exclusion criteria, only those eyes that met the inclusion criteria were selected. Due 
to the small number of patients and that each eye may behave differently thus having 
differing rates of progression, both eyes were included from the same subject. There 
were 50 eyes from 25 patients enrolled in the study. Nature and detail of the study 
were explained to patients. Informed consent was obtained from patients who agreed 
to participate in this study. 
 
Demographic data was documented. A detailed history was acquired from the 
patients regarding age, sex, race, history of systemic diseases, duration of follow-up, 
history of acute PAC, past cataract surgery, and number and type of IOP lowering 
agents used.  
 
Patients underwent 2 times of examination, as outpatient in clinic and as inpatient in 
ward. In clinic, complete ophthalmologic examination, which comprised of slit lamp 
examination, baseline IOP measurement, funduscopy, and gonioscopy. Reliability of 
latest documented HVF test and the previous documented HVF of at least 6 months 
apart were checked. If the test was not reliable, it was repeated and only reliable 
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result was taken. For each eye, AGIS score was calculated from the HVF results.  
Each eye then was grouped into progressed or non-progressed group, based on AGIS 
score of visual field glaucoma progression. Patients subsequently were given date for 
one day ward admission. 
 
During admission in the ward, patients’ vital signs were documented. All oral or 
topical medications including IOP lowering agents were continued. There were 6 
readings of timely IOP measurements. IOP measurements were performed using 
GAT every 4 hours over 24-hour period; at 0800 hour (8 am), 1200 hour (12 pm), 
1600 hour (4 pm), 2000 hour (8 pm), 2400 hour (12 am), and 0400 hour (4 am). IOP 
was measured within 30 minutes after the each point of interval time. All data were 
recorded in the data collection form. Patients were discharged from ward next 
morning, upon completion of latest IOP measurement at 4 am.  
 
3.9.2 Methods of IOP Measurement 
 
3.9.2.1 Goldmann Applanation Tonometer 
 
This procedure was preceded by instillation with a topical anesthetic drop and 
followed by fluorescein dye. The patient was seated at the slit lamp with his/her 
forehead firmly against the headrest and chin comfortably on the chin rest. Patient 
was instructed to look straight ahead and to open eyelids widely. Patient was then 
instructed to blink once to spread the fluorescein dye. Adequate fluorescent staining 
is essential for accurate tonometry. He/She was advised not to blink, squeezing or 
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holding his/her breath. Biprism of tonometer head was moved gently forward until 
just touched the cornea. Knob was slowly and gently adjusted to obtain IOP.  
 
3.9.2.2 Measurement of Mean IOP and Overall Mean IOP 
 
Mean IOP at 4-hourly interval were values of IOP that were averaged at each time 
point were averaged to each group. There were 6 mean IOP for 6 measurements for 
each group. 
In this study, for overall mean IOP during 24-hour period, values of mean IOP from 
6 measurements (at 4-hourly interval) were averaged for each group.   
 
3.9.2.3 Measurement of Mean Peak IOP and Overall Mean Peak IOP 
 
In this study, a single of peak IOP from the 6 measurements was obtained from each 
eye. If one eye had maximum IOP reading at more than 1 interval, the first interval 
of peak IOP reading was taken according to chronological 4-hourly interval. There 
may be none of eyes that had peak IOP reading at a particular interval.  
For mean peak IOP at 4-hourly interval, values of peak IOP at each interval were 
averaged for each group. There were 6 mean peaks IOP for 6 measurements for each 
group. 
For overall mean peak IOP during 24-hour period, values of mean peak IOP from 6 
measurements (at 4-hourly interval) were averaged for each group. 
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3.9.2.4 Measurement of Mean Trough IOP and Overall Mean Trough IOP 
 
In this study, a single of trough IOP from the 6 measurements was obtained from 
each eye. If one eye had minimum IOP reading at more than 1 interval, the first 
interval of trough IOP reading was taken according to chronological 4-hourly 
interval. There may be none of eyes that had trough IOP reading at a particular 
interval.  
For mean trough IOP at 4-hourly interval, values of trough IOP at each interval were 
averaged for each group. There were 6 mean troughs IOP for 6 measurements for 
each group. 
For overall mean trough IOP during 24-hour period, values of mean trough IOP from 
6 times measurement (at 4-hourly interval) were averaged for each group.  
 
3.9.2.5 Measurement of Mean IOP Fluctuation and Overall Mean IOP Fluctuation 
 
Mean IOP fluctuation at 4-hourly interval is defined as the difference between IOP 
values at each interval. IOP at each interval was calculated by subtracting lower IOP 
value from higher IOP value.   
For example, IOP fluctuation at 0800 hour was calculated by subtracting IOP value 
at 1200 hour from IOP value at 0800 hour (whichever lower value, was subtracted 
from the higher value). 
There were 6 IOP fluctuations for 6 measurements for each group. 
For overall IOP fluctuation during 24-hour period, values of IOP fluctuations from 6 
measurements (at 4-hourly interval) were averaged for each group. 
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3.9.2.6 Measurement of Peak Pattern in Circadian Rhythm of IOP 
 
In this study, a single of IOP trough from the 6 measurements of IOP at 4-hourly 
interval was obtained from each eye (refer 3.7.5.2). The point of time that the peak 
pattern occurred was documented. The eye was classified as ‘morning’ peak, if the 
peak was recorded at 0400 or 0800 hour, ‘afternoon’ peak, if recorded at 1200 or 
1600 hour, and ‘night’ peak, if recorded at 2000 or 2400 hour. 
 
3.9.2.7 Measurement of Trough Pattern in Circadian Rhythm of IOP 
 
In this study, a single of IOP trough from the 6 measurements of IOP at 4-hourly 
interval was obtained from each eye (refer 3.7.5.3). The point of time that the trough 
occurred was documented. The eye was classified as ‘morning’ trough, if the trough 
was recorded at 0400 or 0800 hour, ‘afternoon’ trough, if recorded at 1200 or 1600 
hour, and ‘night’ trough, if recorded at 2000 or 2400 hour. 
 
3.9.3 Method of Visual Field Assessment 
 
3.9.3.1 Humphrey Visual Field (HVF) Test 
 
HVF was carried out monocularly. SITA Standard 24-2 program was applied. 
Standard stimulus size III (4mm2) was chosen. Prior to the procedure, patient’s 
refractive error and presbyopia was corrected using appropriate glasses or lens on 
trial frame. Care was taken to center the patient close to correcting lens to avoid a 
lens rim artifact. Pupils were not dilated. Patient was instructed to maintain fixation 
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at central target (yellow light) throughout the procedure, while peripheral vision 
being tested.  
 
3.9.3.2 AGIS score 
 
Patient was further stratified according to severity of the disease using Modified 
AGIS scoring with reliable Humphrey Visual Field (HVF) 24-2 or 30-2 using 
Humphrey Field Analyzer 750i (AGIS 2, 1994). The latest HVF of at least 3 month 
from current visit was used in this study. Reliable HVF was the visual field that was 
reproducible on 2 consecutive visual field analyses. If there was no reliable or latest 
HVF, another HVF was done and considered as latest HVF. This score was obtained 
from the total deviation plot of HVF 24-2 or 30-2. Reliability of visual field was 
based on percentage of fixation loses (less than 20%), false-positive response (less 
than 33%) and false-negative response (less than 33%) (AGIS 2, 1994). The 
unreliable visual field was repeated on the next visit, within 2 to 4 weeks apart. 
However, if after 3 attempts it was still unreliable, the patient was excluded from the 
study and given appointment date as in regular follow up in eye clinic. 
 
A point was considered defective when a minimum amount of sensitivity depression 
was reached. A special transparent plastic was designed according to AGIS score and 
was placed on subject or patient’s HVF. The AGIS score was conducted by Dr 
Haslinda (primary investigator) and masked glaucoma consultant Professor Dr Liza 
Sharmini Ahmad Tajudin re-scored the HVF.  
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The classification of severity was based on mean AGIS score (AGIS 2, 1994). Score 
for each hemifield and for nasal area were summed. The maximum possible score 
was 20 (two for nasal field and nine for each hemifield). Severity was divided into 
five stages. 0 as normal, 1-5 for mild, 6-11 for moderate, 12-17 for severe, 18-20 for 
end stage of glaucoma. 
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3.10 Statistical Analysis 
 
Statistical analysis was performed with the “Statistical Package for Social Sciences” 
(SPSS) for Macintosh version 22 software.  
 
Data exploration and cleaning was done before analysis. Descriptive statistic 
numerical data was checked for normality distribution. Normally distributed data 
was reported using mean and standard deviation, while non-normal or skewed data 
was reported using median and interquartile range. 
 
Univariate analysis was done for comparison of baseline. For numerical data with 
normative value, independent t test was used to compare the means between 2 
independent samples. For skewed distribution data, Mann-Whitney U test was used 
for numerical variable; where as Fisher’s exact test was used for categorical variable. 
In each of the statistical analysis, p value of <0.05 was deemed as statistically 
significant. 
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3.11  Plans Of Minimizing Error  
  
These were the steps used to minimize the errors while conducting the study: 
  
1. Subjects were selected according to the inclusion and exclusion criteria. 
 
2. The same instruments and equipments were used for measurement in the study.  
 
3. The AGIS score was conducted by single primary investigator (Dr Haslinda A. 
Rahim @ Samsuddin) and masked single glaucoma consultant Professor Dr Liza 
Sharmini Ahmad Tajudin re-scored the HVF. 
 
4. The principal investigator (Dr Haslinda A. Rahim @ Samsuddin) was the single 
operator in the measurement of the intraocular pressure.  
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4.1 Demographic Data 
 
4.1.1 General Demographic Data 
 
A total of 50 eyes from 25 PACG patients were included in the study. They were 
grouped into eyes that were progressed and eyes that were non-progressed. The 
progressed PACG consist of 11 eyes, while non-progressed PACG consist of          
39 eyes.  
 
Out of 25 PACG patients, 7 patients had bilateral non-progressed eyes, 2 patients had 
bilateral progressed eyes, and 16 patients had progressed and non-progressed eyes. 
 
In general, patients who had bilateral progressed eyes were older. There was female 
preponderance among PACG patients. Malays outnumbered Chinese patients. 
Hypertension was the commonest systemic co-morbidity. 
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Table 4.1: Demographic data of PACG patients 
 
        Characteristics 
 
PACG patients 
 
N= 25 
Age (mean,SD) 64 (9.4) 
Sex (n,%) 
 
     Male 
 
     Female 
 
 
 
10 (40.0) 
 
15 (60.0) 
 
Race (n,%) 
 
     Malay 
 
     Chinese 
 
 
19 (76.0) 
 
6 (24.0) 
 
Systemic disease (n,%) 
 
     Hypertension 
 
• Yes 
 
• No 
 
     Diabetes mellitus 
 
• Yes 
 
• No 
 
     Hyperlipidemia 
 
• Yes 
 
• No 
 
 
 
 
15 (60.0) 
 
10 (40.0) 
 
 
 
9 (36.0) 
 
16(64.0) 
 
 
 
10 (40.0) 
 
15(60.0) 
Laterality, (n,%) 
 
• Unilateral progressed & non-progressed 
 
• Bilateral progressed 
 
• Bilateral non-progressed 
 
 
16 (64.0) 
 
2 (8.0) 
 
  7 (28.0) 
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4.1.2 Clinical Characteristics 
 
The median intraocular pressure at presentation was slightly higher in progressed 
PACG but this was not statistically significant. There was significant difference for 
duration of diagnosis. Progressed PACG was being followed up longer from initial 
presentation as compared to non-progressed PACG. 
 
There was significant difference for AGIS score at initial diagnosis and at 
requirement.  
 
Peripheral iridectomy was patent in all eyes. There was no significant difference in 
the presence of previous acute primary angle closure, pseudophakia, and central 
corneal thickness (Table 4.2). 
 
All progressed PACG were on either triple or quadruple topical pressure lowering 
agents, which was statistically significant as compared to non-progressed PACG. 
The types of present topical pressure lowering agents also showed significant 
difference (Table 4.3). 
 
 
 
 
 
 
 
 41 
Table 4.2: Comparison of clinical characteristics data between progressed and     
non-progressed PACG 
 
 
Characteristics 
 
Eyes with PACG 
N=50 
 
 
p-value Progressed  
 
n=11 
 
Non-progressed  
 
n=39 
Duration of diagnosis, years 
median (IQR) 
6.0 (6.0) 
 
 
2.0 (2.0) 
 
 
<0.001# 
 
 
Intraocular pressure at 
presentation, mmHg 
median (IQR) 
 
23.0 (14.0) 
 
22.0 (8.0) 
 
 
0.255# 
 
History of previous acute Primary 
Angle Closure (n,%) 
 
4 (36.4) 
 
5 (12.8) 0.093* 
Central corneal thickness, mm  
(mean, SD) 
 
522 (0.2) 
 
513 (0.2) 0.162@ 
 
AGIS score at initial diagnosis (n,%) 
 
None 
 
Mild 
 
Moderate 
 
Severe 
 
 
 
1 (9.1) 
 
2 (18.2) 
 
8 (72.7) 
 
0 (0) 
 
 
0 (0) 
 
29 (74.4) 
 
9 (23.1) 
 
1 (2.6) 
0.001* 
AGIS score at recruitment (n,%) 
 
Mild 
 
Moderate 
 
Severe 
 
 
 
 
0 (0) 
 
2 (18.2) 
 
9 (81.8) 
 
 
 
 
29 (74.4) 
 
9 (23.1) 
 
1 (2.6) 
<0.001* 
Laser peripheral iridectomy (n,%) 11 (100) 39 (100) - 
Pseudophakia (n,%) 5 (45.5) 
 
11 (28.2) 
 
0.233* 
p<0.05 is considered statistically significant based on @independent t-test, #Mann-
Whitney U test, *Fisher’s exact test 
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Table 4.3: Comparison of number and types of topical pressure lowering agents 
between progressed and non-progressed PACG 
 
 
Characteristics 
 
Eyes with PACG 
N=50 
 
 
p-value Progressed  
 
n=11 
 
Non-progressed  
 
n=39 
Number of present topical pressure 
lowering agents (n,%) 
 
             None 
 
Monotherapy 
 
Dual therapy 
 
Triple therapy 
 
Quadruple therapy 
 
 
 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
6 (54.5) 
 
5 (45.5) 
 
 
 
4 (10.3) 
 
17 (43.6) 
 
10 (25.6) 
 
4 (10.3) 
 
4 (10.3) 
<0.001* 
 Types of present topical pressure    
 lowering agents (n,%) 
 
          No drug 
 
          BB alone 
 
          PG alone 
  
          CAI alone 
 
          BB + PG 
 
          BB + CAI 
 
          BB + PG + CAI 
 
          BB + PG + CAI + AB 
 
 
 
 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
0 (0) 
 
6 (54.5) 
 
5 (45.5) 
 
 
 
4 (10.3) 
 
14 (35.9) 
 
2 (5.1) 
 
1 (2.6) 
 
3 (7.7) 
 
7 (17.9) 
 
4 (10.3) 
 
4 (10.3) 
0.001* 
 
 
 
p<0.05 is considered statistically significant based on *Fisher’s exact test 
BB = Beta Blocker, PG = Prostaglandin analogue, CAI = Carbonic Anhydrase 
Inhibiter, AB = Alpha Blocker 
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4.2 Pattern of 4-hour Time Points of IOP Variables in Progressed and  
Non-progressed PACG 
 
In progressed PACG, both mean IOP and IOP peak were at maximum reading at 
0800 hour. Mean IOP were noted at minimum reading at 1200 hour while IOP 
trough was at minimum reading at 2400 hour. 
No progressed eyes had IOP peak at 1200 hour or had IOP trough at 0400 hour. 
Maximum IOP fluctuation occurred at 1200 hour and minimum IOP fluctuation 
occurred at 0400 hour. 
 
Meanwhile, in non-progressed PACG, maximum mean IOP was observed at 0800 
hour with IOP peak of maximum reading at 2400 hour. Minimum mean IOP was 
observed at 2000 hour with minimum IOP trough occurred at 0800 hour. Maximum 
IOP fluctuation occurred at 2400 hour and minimum IOP fluctuation occurred at 
0400 hour. 
 
Generally, mean IOP at 4-hour time points were almost similar between progressed 
and non-progressed PACG from 1600 to 2400 hour. Largest difference was observed 
between groups at 1200 hour. Mean IOP of non-progressed PACG decreased steadily 
from 0800 to 2000 hour, and increased steadily after that. 
 
Progressed PACG showed consistently lower mean IOP fluctuation from non-
progressed eye group between 0800 and 2000 hour. There was a single interval 
where mean IOP of progressed PACG was higher than non-progressed PACG, which 
occurred at 2400 hour, but the difference was small. 
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At 4-hour time points, there were consistent IOP peak readings in non-progressed 
PACG as compared to progressed PACG. Both groups exhibited large difference of 
IOP peak reading at 2400 and 0400.  
 
There were 2 time points of IOP trough where progressed PACG had higher reading 
than non-progressed PACG, which occurred at 0800 and 1600 hour.  Progressed 
PACG exhibited plateau reading of IOP trough between 1200 and 1600 hour, and 
2000 and 2400 hour. IOP trough reading of non-progressed PACG decreased steadily 
from 2000 to 0400 hour. 
 
IOP fluctuation reading at 4-hour time points in progressed PACG decreased steadily 
from 1200 to 0400 hour but it showed consistently higher reading than non-
progressed PACG between 1200 and 2000 hour. Non-progressed PACG had higher 
IOP fluctuation reading than progressed PACG at 2400 to 0400 hour. Both groups 
had overlapping IOP fluctuation reading at 0800 hour. Mean IOP fluctuation at 4-
hour time points ranged between 1.6 to 3.0 mmHg in progressed PACG, and it 
ranged 2.0 to 2.9 mmHg in non-progressed PACG. 
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 Figure 4.1 Mean IOP in progressed and non-progressed PACG at 4-hour time points 
 
 
 
Figure 4.2 Mean of IOP peak in progressed and non-progressed PACG at 4-hour 
time points 
6.08.0
10.012.0
14.016.0
18.020.0
22.024.0
0800 1200 1600 2000 2400 0400Mea
n 
In
tr
ao
cu
la
r 
Pr
es
su
re
 (m
m
H
g)
 
Time (hour) 
Progressed eye group
Non-progressed eyegroup
0.02.04.0
6.08.010.0
12.014.016.0
18.020.022.0
24.0
0800 1200 1600 2000 2400 0400Intra
oc
ul
ar
 P
re
as
su
re
 P
ea
k 
(m
m
H
g)
 
Time (hour) 
Progressed eye group
Non-progressed eyegroup
 46 
 Figure 4.3 Mean of IOP trough in progressed and non-progressed PACG at 4-hour 
time points 
 
 
 
Figure 4.4 Mean of IOP fluctuation in progressed and non-progressed PACG           
at 4-hour time points 
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4.3 Pattern of Circadian Rhythm of IOP in Progressed and Non-progressed 
PACG 
 
Majority of progressed PACG showed patterns of night peak with afternoon trough, 
while non-progressed PACG exhibited patterns of afternoon peak with night trough. 
This is however not statistically significant. 
 
Table 4.4: Comparison of peak and trough pattern between progressed and non-
progressed PACG 
 
Characteristics 
Eyes with PACG 
N=50 
 
p-value* 
Progressed 
n=11 
Non-progressed 
n=39 
Peak (n,%) 
      Morning 
      Afternoon 
      Night 
 
4 (16.7) 
2 (13.3) 
5 (45.5) 
 
20 (83.3) 
13 (86.7) 
6 (54.5) 
0.130 
Trough (n,%) 
      Morning 
      Afternoon 
      Night 
 
 
1 (20) 
6 (26) 
4 (18.2) 
 
4 (80) 
17 (73.9) 
18 (81.8) 
0.881 
p<0.05 is considered statistically significant based on *Fisher’s exact test 
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4.4 Comparison of 24-hour Intraocular Pressure Variables between Progressed 
and Non-progressed PACG  
 
There was no significance difference for 24-hour mean IOP, IOP peak, IOP trough, 
and IOP fluctuation between progressed and non-progressed PACG. 
 
Table 4.5: Comparison of 24-hour mean IOP, IOP peak, IOP trough, and IOP 
fluctuation between progressed and non-progressed PACG 
 
 
 
Characteristics 
Eyes with PACG 
N=50 
 
 
 
p-value# 
Progressed 
 
n=11 
 
Non-progressed 
 
n=39 
24-hour IOP, mmHg  
(median, IQR) 
 
13.7 (3.2) 
 
15.3 (5.5) 0.202 
24-hour IOP peak, 
mmHg  
(median, IQR) 
 
17.0 (3.0) 18.0 (5.0) 0.285 
24-hour IOP trough, 
mmHg  
(median, IQR) 
 
11.0 (4.0) 13.0 (4.0) 0.151 
24-hour IOP 
fluctuation, mmHg 
(median, IQR) 
 
6.0 (3.0) 6.0 (3.0) 0.803 
IQR = Interquartile Range 
p<0.05 is considered statistically significant based on #Mann-Whitney U test 
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5.1 Discussion 
 
Visual field progression among PACG patients was less extensively studied as 
compared to glaucoma progression of angle closure between subtypes from PACS to 
PAC, and PAC to PACG. It was well known that the natural course of PACG begins 
with PACS, which may worsen to become PAC and further developed into PACG 
(Aung, 2005). Once glaucomatous damage has occurred, there was 16-fold increased 
risk of progression in Malays PACG patients (Liza-Sharmini et al., 2014).  
 
IOP is among important risk factors contributing to glaucoma progression, apart 
from other factors such as thinner CCT, short axial length, glaucomatous changes at 
presentation, advanced VF defect at presentation, presence of APAC, absence of 
laser PI, older age, Malay ethnic, lower blood pressure, and presence of migraine 
(Hong et al, 2007; Fan et al, 2013; Liza-Sharmini et al, 2014; Quek et al, 2011; 
Leske et al, 2004; Sharmini et al, 2009; Drance et al, 2001).  
 
High IOP alone was insufficient to explain the progression of glaucomatous optic 
neuropathy in patients with ‘normal’ IOP during clinic visits. More studies are 
looking into wide diurnal IOP fluctuation in addition to high mean IOP as significant 
risk for glaucoma progression (Asrani et al., 2000; Nouri-Mahdavi et al., 2004; Singh 
& Shrivastava, 2009). Diurnal and nocturnal IOP recordings are difficult and pose a 
practical challenge for both clinician and patients. Many studies required hospital 
admission for nocturnal IOP recordings.  It has to be borne in mind that the effort of 
recording IOP during sleep itself can be a confounding factor (Weinreb & Liu, 
2006). 
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In general, the progression rate of PACG was related to higher average of highest 
IOP in each year of follow up (Lee et al., 2004). Currently, high mean IOP and wide 
IOP fluctuation was consistently demonstrated as important predictors of glaucoma 
progression. However, majority of the studies were conducted on POAG rather than 
PACG subjects (Coleman et al., 2004; Bengtsson et al., 2007; Caprioli & Coleman, 
2008; Anderson, 2003; Asrani et a.l, 2000).  
 
The progressed and non-progressed PACG in this study were determined based on 
AGIS score from Humphrey visual field test. AGIS scoring system was chosen as it 
has greater reproducibility, good specificity, and high sustainability (Katz, 1999; 
Heijl et al, 2008). AGIS system is an event-based progression analysis, that 
determines VF progression to be either present or absent depending on a predefined 
change in the VF parameters (Rao et al, 2013). However, AGIS system was seldom 
used in glaucoma studies nowadays as it was very conservative. Trend-based 
progression analysis such as VF index, was preferred as it provides the actual rate of 
change in the VF parameters (Rao et al, 2013). From this analysis, the rate of 
progression (ROP) can also be determined so that the treatment can be more 
aggressive in fast progressers. In our clinic setting, we have limitations of using VFI 
for regular monitoring of glaucoma progression due to inadequate facilities to 
accommodate high number of glaucoma patients turnover.  
 
Sample size calculation in our study was based on Baskaran’s work (Baskaran et al, 
2009). Standard deviation of mean IOP of 1.24 mmHg was used. However for better 
accuracy, standard deviation of IOP fluctuation should be considered instead of mean 
IOP alone. Since the standard deviation of mean IOP fluctuation was 2.4 mmHg 
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(Baskaran et al, 2009) as compared to mean IOP of 1.24 mmHg (Baskaran et al, 
2009), it is expected the sample size to be increased by minimum of 3-folds which 
render longer duration of study period. 
 
A total of 50 eyes from 25 PACG patients were included in the study. They were 
grouped into eyes that were progressed and eyes that were non-progressed. The 
progressed eye group consist of 11 eyes, while non-progressed eye group consist of 
39 eyes. We had included bilateral eyes of patients diagnosed with PACG, where one 
eye may be grouped in progressed PACG and the fellow eye may be grouped in non-
progressed PACG. Both eyes also may be grouped into one similar group. Majority 
of our patients had non-progressed eyes bilaterally. Non-progressed eye group had 
larger sample size than the progressed group. There is possibility of symmetry of 
right versus left IOP over 24 hours in a patient’s eyes, as proposed by Sit and 
colleagues. They observed that there was moderate strength of association between 
IOPs of right and left eyes in untreated glaucoma patients (Sit et al, 2005).  This 
condition may apply to a patient’s eyes that were grouped into different groups of 
progressed and non-progressed PACG.  
 
We had included pseudophakic patients in our study. As widely known, the 
crystalline lens is a major contributor of angle closure in PACG patients. Cataract 
extraction has been found to indirectly relieve pupillary block and lower IOP in 
angle closure glaucoma. It helps to widen the narrow angle, deepen the anterior 
chamber, and attenuate the anterior positioning of ciliary processes (Aung et el., 
2001). But once the lens is removed, the widening of anterior chamber angle can blur 
the distinction between open-angle and angle-closure glaucoma.                           
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Thus in future study, it is recommended that pseudophakia is one of exclusion 
criteria. 
 
As in nature course of any chronic disease; the longer the duration of the disease 
there is the higher risk to progress. Length of follow up also has been found to be a 
risk factor for glaucoma progression (Nouri-Mahdavi et al., 2004). Progressed eye 
PACG in this study were being followed up longer at average 6 years as compared to 
non-progressed eye group of PACG at average 2 years, which was statistically 
significant. The differences in follow-up duration between the groups substantively 
may weaken the comparisons of the 24-hour IOP profiles. Thus, comparable of 
follow-up period between groups will definitely provide more valuable data. 
 
There was also significant difference in number and types of pressure lowering 
agents in both groups. All progressed eyes were on more than 3 topical pressure 
lowering agents as compared to non-progressed eyes whom majority were on less 
than 2 medications.   The 24-hour IOP profile would have corresponded to the effect 
of IOP lowering medications, not the angle closure alone. Hence the washout period 
may overcome the medication effect. However in this study we opted to continue 
with patients’ current medications as the PACG eyes were at risk for acute attack and 
fast deterioration of neuropathy especially those eyes with severe stage of disease.  
 
From this study, we observed almost similar pattern of some IOP variations at 4-hour 
time points between progressed and non-progressed PACG.  In both groups, highest 
mean IOP was recorded in the morning, which was at 0800 hour with maximum IOP 
peak reading. While lowest mean IOP was recorded at noon in progressed eyes, non-
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progressed eyes exhibited lowest mean IOP at night. Majority of progressed PACG 
showed patterns of night peak with afternoon trough, while non-progressed PACG 
exhibited patterns of morning peak with night trough. This result was in agreement 
with other studies, which reported that IOP peak in PACG subjects was observed at 
various time in the morning, afternoon, early morning, and also midnight (Sihota et 
al., 2005; Leydhecker, 1976; Shapiro & Zauberman, 1979).  
 
Over 24-hour period, non-progressed PACG exhibited slightly higher reading of 
mean IOP, IOP peak, and IOP trough than progressed PACG even though it was not 
statistically significant. Mean IOP was significantly higher in progressed than non-
progressed PACG and significantly associated with PACG progression, as showed in 
other 2 studies (Sharmini et al, 2009; Quek et al, 2011). Sharmini and workers also 
recommended that mean IOP target should be equal or less than 12 mmHg as they 
observed none of their PACG patients progressed with the IOP reading, while more 
than half of the patients progressed with IOP of equal or more than 22 mmHg. On 
the other hand, Quek and friends documented 33% of their treated PACG patients 
progressed over 10 years, and 5 to 10% progressed to blindness over similar period. 
Again, these 2 studies differ from our study in terms of setting and duration of IOP 
measurements. 
 
A study by Lee and colleagues, which compared rate of VF progression between 
PACG and POAG, demonstrated that VF progression was faster in PACG. In PACG, 
progression of VF loss was significantly correlated with mean IOP, IOP peak, and 
IOP trough (Lee et al, 2004). Konstas and associates conducted a study in POAG and 
they concluded that 24-hour IOP peak is an independent risk factor for POAG 
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progression (Konstas et al, 2012). Both also differ from our study as they compared 
either PACG and POAG, or progressed and non-progressed POAG.  
 
There are various definitions for IOP fluctuation. In our study, we defined IOP 
fluctuation as difference between IOP measurements at each time points by 
subtracting lower IOP value from higher IOP value.  The 24-hour IOP fluctuations 
were the mean of IOP fluctuations from all time points. Other definition of IOP 
fluctuation is the standard deviation of IOP measurements (Baskaran et al, 2009; Rao 
et al, 2013). We used this definition for our study because the IOP was measured 4-
hourly around the clock. Different setting of methodology of IOP fluctuation 
measurements in other studies were conducted, for example Baskaran’s work 
employed only diurnal period. On the other hand, Rao’s study was conducted over 
more than 5 years follow up with different time of single office hour IOP 
measurement at 3 to 6-monthly interval.  
 
In our study, IOP fluctuation over 24-hour recordings was 6.0 mmHg in both groups. 
High diurnal IOP fluctuation of within range of 4-8 mmHg has been observed in 
PACG eyes (Baskaran et al., 2009; Sihota et al, 2005). Our finding was in agreement 
with both studies. However, there was no significant difference between progressed 
and non-progressed PACG for 24-hour IOP fluctuation. This was an unexpected 
result, considering that greater IOP dependence for optic nerve damage was observed 
in PACG (Gazzard et al, 2003). Small sample size, bilateral eyes inclusion, and 
different duration of follow-up may contribute to this insignificance result. 
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Rao and colleagues had investigated relationship between IOP and rate of VF 
progression in treated PACG. They found out that IOP fluctuation was significantly 
associated with PACG progression. Each 1 mmHg increase in IOP fluctuation will 
worsen the progression by 0.35% per year (Rao et al, 2013). Another work by Hong 
and associates pointed that larger long term IOP fluctuation was associated with 
PACG progression even though IOP maintained low post triple procedure (Hong et 
al, 2007). These 2 studies concluded the significance of IOP fluctuation as risk factor 
for PACG progression, but none are comparable to our study. Both studies took 5 to 
10 years of follow-up, and single office visit mean IOP was taken. Our studies 
recorded a one-day IOP profile, which was 24-hour IOP measurement of 6 time 
points.  Hence our study were subjected to short-term IOP fluctuations, where as 
their studies were prone to long-term IOP fluctuations. Furthermore, one of the 
studies recruited post triple procedure patients where as our study excluded patients 
post filtering surgery. 
 
Regarding circadian rhythm of IOP, normal non-glaucoma people were observed to 
have morning and night peak, while the trough occurs in the afternoon. This normal 
circadian rhythm is explained by the physiology of aqueous production and outflow 
as well as the change in body position (Grehn and Stamper, 2009). Aqueous 
production is maximized during daytime with morning peak, thus giving rise to IOP 
peak at that point of time. To add on, multiple ‘stressful’ activities in the morning to 
start the day with such as quick preparing and sending children to school, rushing to 
workplace, and settling last minute errands also indirectly might justify the IOP peak 
in the morning. During daytime, the body is mostly in sitting or upright position. The 
effect of gravity in that position contributes to the trough that occurs in the afternoon, 
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facilitating aqueous humor outflow despite its maximum production. The body is 
also in more relaxed condition in the afternoon after settling the ‘stressful’ morning 
activities. At night, while aqueous production decreased by 50% or more, there is 
also reduction in outflow facility as the body changes its position from seated to 
supine, in which causes episcleral venous pressure to raise. This results in peak of 
IOP at nighttime. 
 
In glaucoma patients, the circadian rhythm of IOP has been known to be interrupted 
and dysfunction (Jean-Louis et al., 2008; Fogagnolo et al., 2009). Progressed PACG 
demonstrated night peak while non-progressed PACG exhibited morning peak. For 
trough, progressed PACG showed afternoon trough while non-progressed PACG 
showed night trough.  
 
In our study, we found that the progressed eye group of PACG followed the normal 
circadian control of IOP, but this was not the case with the non-progressed eye 
group. This could be explained by significant difference of pharmacotherapy 
between both groups. Majority of progressed eyes received prostaglandin analogue 
in their treatment. Prostaglandin analogue has been claimed to maintain a significant 
IOP reduction around-the-clock hence plays an important role in circadian IOP 
management (Mishima et al., 1997). It helps to increase uveoscleral outflow 
especially nighttime where the aqueous humor outflow facility is at minimum level.  
 
Apart from that, there are factors affecting IOP fluctuation measurement that should 
be addressed. In this study, we admitted our patients to hospital ward for 24 hours. 
As GAT was used as IOP measurement, patients had to be awake during 
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examination. Patients also had to walk from bed, entered examination room, and 
properly seated for IOP measurement. Some of the patients were unable to sleep 
overnight probably because of sudden change in environment. Sleep also was 
disturbed by frequent repeated IOP measurements. Their activity daily living routine 
were mostly interrupted as compared to when they were at home. The short-term IOP 
fluctuation may not be significantly manifested while in the ward. Furthermore, IOP 
measurement was taken in sitting upright position, abolishing habitual position 
during sleep time. This could mask the actual IOP reading and produce erroneous 
result as compared to measurement in supine position. 
 
This study would be more interesting if normal population also was being recruited 
as control, in which more significant and reliable results may be produced in 
comparing normal and abnormal subjects especially in IOP variations analysis. 
Factors that may affect IOP fluctuation such as extent of peripheral anterior 
synechiae (PAS) also should have been explored, evaluated, and correlated. 
  
At this point, issue of IOP fluctuation should be our main concern. The single IOP 
reading at achieved IOP target during regular clinic visit does not guarantee that the 
glaucoma progression has come to a halt. Ideally, more effective IOP stabilization 
may be achieved with surgical intervention, which is the glaucoma filtering surgery. 
As for the non-progressed PACG, they should be closely followed-up for a longer 
duration. Focusing on both reduction of mean IOP and IOP fluctuation should be the 
main agenda and targets. This group will definitely progress if we neglect either one 
of those. Maximum pharmacotherapy should be exercised to selected patients. 
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Maybe finally, glaucoma filtering surgery ought to be also considered in resistant 
cases.  
 
Even though this study was limited with the previously discussed factors, it has 
provided a new insight to our clinical practice about 24-hour profile of IOP 
fluctuation in PACG patients. 
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5.2 Limitations and Recommendation 
 
We highlighted several limitations in our study and the recommendations for future 
studies. 
 
1. Due to small sample size, we had included both eyes. In the future, a larger sample 
size of one eye for each patient is recommended. 
 
2. There is unequal number of samples for each group thus most of the data were 
skewed and nonparametric statistics were applied. This resulted in lower degree of 
confidence than if the results were obtained using parametric statistics. In the future, 
equal number of samples for each group is recommended so that normal distribution 
of data can be achieved.  
 
3. There is no recruitment of normal population as control. In the future, matched 
control group is recommended. 
 
3. In our study, patients need ward admission for 24-hour period. IOP measurements    
were taken with GAT in sitting position. This was likely affecting the IOP readings 
in our study, thus the result may not be as accurate as in patients’ usual environment 
and habitual position. In the future, we recommend handheld mobile device such as 
ICare One tonometer for recording IOP and IOP monitoring at home. IOP 
measurements should be taken in habitual position with minimal interruption of 
activity daily living routine. 
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4. There was no washout period for patients that were on medications in this study. 
In the future, washout period prior to IOP measurements is recommended. 
 
5. There was no evaluation of factors affecting IOP fluctuation such as peripheral 
anterior synechiae. In the future, factors affecting IOP fluctuation as above is 
recommended. 
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6.0 CONCLUSION 
 
1.  In progressed PACG, the 24-hour median IOP was 13.7 mmHg, 24-hour IOP 
peak was 17.0 mmHg, 24-hour IOP trough was 11.0 mmHg, and 24-hour IOP 
fluctuation was 6.0 mmHg. 
 
2. In non-progressed PACG, the 24-hour median IOP was 15.3 mmHg, 24-hour 
IOP peak was 18.0 mmHg, 24-hour IOP trough was 13.0 mmHg, and 24-hour IOP 
fluctuation was 6.0 mmHg. 
 
3. There was no significant difference of 24-hour IOP, IOP peak, IOP trough, 
and IOP fluctuation between progressed and non-progressed PACG. 
 
4. Circadian rhythm of IOP in progressed PACG showed patterns of night peak 
with afternoon trough, while non-progressed PACG exhibited patterns of afternoon 
peak with night trough. This was however not statistically significant. 
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 APPENDIX A: Clinical Record Form 
 DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICAL SCIENCES, UNIVERSITI SAINS MALAYSIA 
A. BIODATA OF PATIENT 
1. Registration Number (RN) :  ______________ 
2. Phone number   Home:  ______________ 
Mobile:______________ 
3. Address   _____________________________________________ 
________________________________________________________ 
4. Date of birth __________ 
5. Age  __________ 
6. Gender M / F 
7. Ethnicity Malay / Chinese / Indian / Others: __________ 
8. Nationality  Malaysian / Non-Malaysian (please state: ____________) 
 
B. SYSTEMIC DISEASE 
a. Diabetes mellitus   
b. Hypertension 
c. Hypercholesterolemia 
d. Autoimmune disease 
e. Tuberculosis 
f. HIV/Hep B/Hep C 
g. Cancer 
h. Other diseases :
 _________________ 
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 C. OCULAR DISEASE (NON-GLAUCOMA) 
OD OS 
  
  
  
 
D. DIAGNOSIS and EXAMINATION AT FIRST PRESENTATION 1.PACG   Acute   Non-acute  2. AGIS score  ______     Mild        Moderate     Severe     End-stage   3. Visual Acuity  OD    OS     ph     ph   
4. Anterior segment  OD    OS 
 
 
 
 
5. Intraocular pressure      OD _______     OS _______  
6.Posterior segment      7. Gonioscopy  OD    OS       8. Date of Diagnosis: __________________       Duration of Glaucoma: ______________ 9. Visual Field:   OD MD/PSD _________________________________ 
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   OS MD/PSD_________________________________  10. Number and type of topical antiglaucoma eye drops   
OD OS 
1. 1. 
2. 2. 
3. 3. 
4. 4.          10. Laser PI  OD       _________ OS ____________ 
 
11. Cataract surgery    OD __________ OS      __________ 
 
E. EXAMINATION AT CURRENT PRESENTATION  1. AGIS score  ______     Mild        Moderate     Severe     End-stage   3. Visual Acuity  OD    OS     ph     ph   
4. Anterior segment  OD    OS 
 
 
 
 
5. Intraocular pressure      OD _______     OS _______  
6.Posterior segment    7. Gonioscopy  OD    OS       9. Visual Field:   OD MD/PSD _________________________________ 
 77 
   OS MD/PSD__________________________________  10. Number and type of topical antiglaucoma eye drops    
OD OS 
1. 1. 
2. 2. 
3. 3. 
4. 4.   11. Laser PI  OD       _________ OS ____________   12. Cataract surgery    OD __________ OS      __________  13.  OCT (RNFL analysis)  OD       _________ OS ____________  14.  CCT          OD       _________ OS ____________  9. Fundus photo          OD       _________ OS ____________   
F. SYSTEMIC EXAMINATION 1. Weight 2. Height 3. BMI 4. BP        
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APPENDIX B: Patient Information Sheet 
Patient Information Sheet and Consent Form    
The Effect Of 24-Hour Intraocular Pressure Fluctuation On Glaucoma 
Progression In Primary Angle Closure Glaucoma 
 
Researcher’s Name: Dr. Haslinda A.Rahim @ Samsuddin 
Supervisor's Name: Associate Professor Dr. Azhany Yaakub 
Co Supervisor's Name: Professor Dr. Liza Sharmini Ahmad Tajudin 
 
Introduction   You are invited to participate in a study on : 
The Effect Of 24-Hour Intraocular Pressure Fluctuation On Glaucoma 
Progression In Primary Angle Closure Glaucoma. Before you agree to take part, it is important that you read and understand about the information written on this sheet. It describes the purpose, procedure, benefit, side-effects and precautions about the study. It also explains about your right to withdraw yourself from this study at any stage of the study. If you agree, you will receive one copy of this information sheet for your reference. It is estimated that 56 patients will participate in this study. It will be carried out in Ophthalmology Clinic and Ophthalmology Ward (2 UTARA) Hospital Universiti Sains Malaysia; from May 2012 to May  2014.  
Purpose of this study The objective of this study is to determine and compare the pattern of IOP fluctuation in patients with primary angle closure glaucoma and  its effect on glaucoma progression. Any study related information that identifies you will remain confidential and will not be made publicly available. The data obtained will only be used for literature publication and scientific interest.  
Qualification to Participate  The doctor in-charged or the staff in this study will discuss with you concerning the eligibility to participate in this study. It is therefore important for you to reveal the detail of your health and medical history accurately.  The selection is based on the inclusion criteria as follow and you are not able to take part in the study if you do not fulfill all the following criteria; 
1. Able to understand the nature of the study and willing to sign written consent 
form. You are not eligible if you 1. Unable to understand the nature of the study and not willing to sign written consent form.    
Study Procedures First visit: You will be approached if you are eligible for the study.  Second visit: 
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You will be admitted for 24 hours and 4 hourly IOP measurement will be taken.  
Participation in this Study  Your participation in this study is entirely voluntary. You may refuse to take part in this study or you may stop your participation in this study at anytime, without penalty or loss of benefits to which you are otherwise entitled.  Your participation may also be stopped by the study doctor without your consent.  
Treatment and Compensation for Injury If you follow the instruction, any physical injury as a result of the procedure that was given to you as required by the study, will be covered by the sponsors when it is not covered by the insurance, government programmes or other third party. 
Possible Benefits You may not have any direct benefit from the participation of the study. You may obtain information regarding your eye’s health condition and laboratory test that may be provided in the study.  However, your participation in this study will give us some information which might help us treat our future patients better.  
Confidentiality Your medical records will be kept confidential and will not be disclosed in public unless requested by the law. Data obtained from this study that does not identify you individually may be published. The original medical record may be seen by the ethical committee for certification of the procedure and clinical data.  Your medical information may be held and processed on a computer.  
Signature By signing this consent form, you authorize the record review, information storage and data transfer. To take part in this study, you or your legal guardian must sign and date the consent form.   Should you have any question or doubt regarding this study or concerning you rights, please contact 
1. Dr Haslinda A.Rahim @ Samsuddin (012-8081775)          
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Borang maklumat dan keizinan peserta  
 
Kajian Dua Puluh Empat Jam Turun Naik Tekanan Intraokular Ke Atas 
Kemajuan Glaucoma Di Kalangan Pesakit Glaukoma Primer Sudut 
Tertutup. 
 
Nama Penyelidik: Dr. Haslinda A.Rahim @ Samsuddin 
Nama Penyelia: Associate Professor Dr. Azhany Yaakub 
Nama Penyelia Bersama: Professor Dr. Liza Sharmini Ahmad Tajudin  
 
Pengenalan Anda dipelawa untuk menyertai satu kajian penyelidikan secara sukarela yang melibatkan pengukuran tekanan intraokular dalam masa 24 jam. Sebelum anda bersetuju untuk menyertai kajian penyelidikan ini, adalah penting anda membaca dan memahami tentang apa yang ditulis di dalam borang ini. Borang ini akan menghuraikan tujuan, prosedur, manfaat, risiko , ketidakselesaan dan langkah berjaga-jaga kajian ini. Ia juga menghuraikan hak anda untuk menarik diri dari kajian ini pada bila-bila masa. Sekiranya anda menyertai kajian ini, anda akan menerima satu salinan borang ini untuk disimpan sebagai rekod anda. 
Tujuan Kajian Kajian ini bertujuan untuk menentukan corak turun naik tekanan intraokular dalam masa 24 jam dan kesannya ke atas kemajuan glaucoma. Segala  maklumat yang diperolehi daripada anda akan dirahsiakan oleh kami. Semua data yang diperolehi daripada anda hanya akan digunakan untuk penulisan ilmiah dan pembentangan kertas-kertas saitifik. Data yang diperolehi adalah dianggap SULIT. 
Kelayakan Penyertaan Doktor yang bertanggungjawab dalam kajian  ini atau salah seorang kakitangan kajian telah membincangkan kelayakan untuk menyertai kajian ini dengan anda. Adalah penting anda berterus terang dengan doktor dan kakitangan tersebut tentang sejarah kesihatan anda. Anda tidak seharusnya menyertai kajian ini sekiranya anda tidak memenuhi semua syarat kelayakan. Keperluan untuk menyertai kajian ini adalah : 
1.Anda faham tentang kajian ini dan setuju untuk menandatangi surat keizinan Anda tidak boleh menyertai kajian ini sekiranya : 
1.Anda tidak faham tentang kajian ini dan tidak bersetuju untuk menandatangani 
surat keizinan  
Prosedur-prosedur Kajian 
Lawatan pertama Anda akan dipelawa untuk menyertai kajian ini sekiranya anda didapati layak. 
Lawatan kedua Anda akan dimasukkan ke wad selama 24 jam dan setiap 4 jam tekanan intraocular akan direkodkan. 
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Penyertaan Dalam Kajian Penyertaan anda dalam kajian ini adalah secara sukarela. Anda boleh menolak penyertaan dalam kajian ini atau anda boleh menamatkan penyertaan anda dalam kajian ini pada bila-bila masa, tanpa sebarang hukuman atau kehilangan sebarang manfaat yang sepatutnya diperolehi oleh anda. Keputusan anda akan diterima tanpa sebarang prasangka. Penyertaan anda mungkin juga diberhentikan oleh doktor kajian tanpa persetujuaan anda sepertimana dinyatakan sebelum ini. Jika anda berhenti menyertai kajian ini, doktor kajian atau salah seorang kakitangan akan berbincang dengan anda mengenai apa-apa isu perubatan berkenaan dengan pemberhentian penyertaan anda. 
 
 
Manfaat yang Mungkin Ubat dan prosedur kajian akan diberikan kepada anda tanpa kos. Anda mungkin menerima maklumat tentang kesihatan anda dari apa-apa pemeriksaan fizikal dan ujian makmal yang bakal dilakukan dalam  kajian ini. Maklumat yang didapati mungkin memanfaatkan pesakit pada masa depan. Sekiranya anda mempunyai sebarang soalan mengenai kajian ini atau hak-hak anda, sila hubungi 
- Dr Haslinda Binti A.Rahim @ Samsuddin (012-8081775)              
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APPENDIX C: Consent Form 
Patient Information and Consent Form ( Signature Page ) 
 
Research Title        :  The Effect Of 24-Hour Intraocular Pressure Fluctuation 
On Glaucoma Progression In Primary Angle Closure Glaucoma 
 
Researcher’s Name: Dr. Haslinda A.Rahim @ Samsuddin 
Supervisor's Name: Associate Professor Dr. Azhany Yaakub 
Co Supervisor's Name: Professor Dr. Liza Sharmini Ahmad Tajudin 
 To become a part this study, you or your legal representative must sign this page.     By signing this page, I am confirming the following: 
1. I have read all of the information in this Patient Information and Consent 
Form including any information regarding the risk in this study and I have 
had time to think about it. 
2. All of my questions have been answered to my satisfaction. 
3. I voluntarily agree to be part of this research study, to follow the study 
procedures, and to provide necessary information to the doctor, nurses, or 
other staff members, as requested. 
4. I may freely choose to stop being a part of this study at anytime. 
5. I have received a copy of this Patient Information and Consent Form to 
keep for myself.  __________________________  ________________________________ (Patient’s signature)     Date                                   Patient’s name:          IC number:  __________________________  ________________________________ Signature of legal guardian    Date    Name:           IC number:  __________________________  ________________________________ Signature and name of investigator  Date Name: IC number: __________________________  ________________________________ Signature of witness     Date    Name:            IC number:    
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Borang Maklumat dan Keizinan Pesakit (Halaman Tandatangan) 
 Untuk menyertai kajian ini, anda atau wakil sah anda mesti menandatangani mukasurat ini.   Dengan menandatangani mukasurat ini, saya mengesahkan yang berikut: 
- Saya telah membaca semua maklumat dalam Borang Maklumat dan 
Keizinan Pesakit ini, dan saya telah diberi masa yang mencukupi untuk 
mempertimbangkan maklumat tersebut. 
- Semua kemusykilan saya telah dijawab dengan jawapan yang 
memuaskan. 
- Saya, secara sukarela, bersetuju menyertai kajian penyelidikan ini, 
mematuhi segala prosedur kajian dan memberi maklumat yang diperlukan 
kepada doktor, para jururawat and juga kakitangan lain yang berkaitan 
apabila diminta. 
- Saya boleh menamatkan penyertaan saya dalam kajian ini pada bila-bila 
masa. 
- Saya telah menerima satu salinan Borang Maklumat dan Keizinan Pesakit 
untuk simpanan peribadi saya. ___________________________  ______________________________ Tandatangan Pesakit      Tarikh Nama Pesakit:         No. Kad Pengenalan:  ____________________________  ______________________________ Tandatangan Wakil Sah Pesakit     Tarikh Nama: No. Kad Pengenalan:       ____________________________  ______________________________ Tandatangan Individu yang Mengendalikan    Tarikh Perbincangan Keizinan (Ditera atau Ditaip) Nama: No. Kad Pengenalan:  ____________________________  _____________________________ Tandatangan Saksi        Tarikh Nama: No. Kad Pengenalan:    
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APPENDIX D: Flow Chart of Methodology   
 
 
 
 
 
 
 
 
 
 
 
(AGIS score) 
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Glaucoma patients at Hospital USM 
Primary Angle Closure Glaucoma 
N=50 
I 
Progressed group 
n=ll 
.. 
l 
Non-progressed group 
n=39 
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Abstract  
We demonstrated a non-invasive management of early bleb leak following trabeculectomy using 
cyanoacrylate tissue glue (CATG). Three patients who underwent augmented trabeculectomy 
with mitomycin C with early bleb leak between January 2009 to June 2010 were reviewed. Case 
1 and case 2 were noted bleb leak at postoperative day 1 and case 3 was noted  leak on follow 
up at postoperative day 7. Case 1 was successfully sealed with CATG at postoperative day 3, 
after failed pressure padding and bandage contact lens . Case 2 was successfully sealed with 
CATG at postoperative day 3, after failed pressure padding and conjunctiva flap resuturing. In 
case 3, the leakage conjunctival flap was managed with combined techniques of resuturing and 
applying CATG at postoperative day 9, after failed pressure padding. During leakage, the 
intraocular pressure was low (6-8 mmHg) in all three cases with shallow anterior chamber depth, 
and absence of other complications  such as choroidal detachment, hypotony maculopathy or 
endophthalmitis. Foreign body sensation was the main complaint following the procedure. No 
clinical allergy reaction was documented. CATG may serve as one of the potential adjunctive and 
effective methods in the management of post-trabeculectomy  with early bleb leak. 
 
Key words: cyanoacrylate tissue glue, bleb leak, trabeculectomy,  mitomycin C 
 
Introduction 
Trabeculectomy is a surgical glaucoma procedure that aims to lower the intraocular pressure 
(IOP) by creating a fistula for aqueous drainage from anterior chamber to subtenon space. Lower 
IOP will prevent further insult to the optic nerve and hence further visual field loss. Mitomycin C 
(MMC) is commonly used as adjunctive treatment in trabeculectomy in order to increase the 
survival of filtering bleb. However, MMC also increases the incidence of bleb leak. Bleb leakage 
that occurs within the first 1 month following trabeculectomy is considered an early postoperative 
leak, and it is frequently encountered as unfortunate complication.1 Its incidence varies from 0% 
to 30%.2  The bleb leak may be self-limiting or complicated with shallow and flat anterior 
chamber, cataract formation, choroidal detachment and hypotony maculopathy. 3 Risk of bleb-
related infection increases up to 26 folds following bleb leakage.4   
 
Conservative measures and medical approaches have been practiced prior to consideration of 
surgical retreatment in bleb leak cases. These include pressure patching, bandage soft contact 
lens, collagen shield, sclera shell tamponade, aqueous suppressants, compression suture, 
conjunctiva suturing, trichloroacetic acid, and autologous blood injection.5 For decades, surgical 
repair or wound revision has been a gold standard in management of leaking bleb. Until recently, 
application of tissue adhesive has been widely accepted as suture alternative. The use of 
cyanoacrylate tissue glue (CATG) has been successfully reported in ophthalmology literatures; 
from sealing corneal perforations to closure of retinal breaks and reattachment of retina in retinal 
detachment cases.6 
 
Cyanoacrylate belongs to a family of polymer.  Liquid form of cyanoacrylate consists of 
monomers of cyanoacrylate molecules, clear colourless appearance with strong odour. The ester 
form of cyanoacrylate, N-butyl cyanoacrylate, is one of the adhesive components which have 
been widely used in medical and veterinary applications.7 Cyanoacrylate liquid monomers rapidly 
solidify by polymerization and form a firm adhesive bond when coming into contact with weak 
base released by little heat, as well as in presence of ionic substances like moisture, blood or 
tissue fluids.7 In polymerized form, its tensile strength of bonding has been observed as the 
highest among all glues.  It also has bacteriostatic property.8 Another alternative of adhesives 
available include biological fibrin glue; a blood-derived product gelatin and thrombin products, 
albumin and glutaraldehyde products, as well as polyethylene glycol polymers.9 
 
We reported 3 successfully sealed early bleb leak cases with CATG. We have used GluStitch®, 
an N-Butyl-2-cyanoacrylate tissue adhesive type.  
 
 
 
Case series  
We retrospectively analyzed the outcome of three patients with early leaking filtering blebs 
managed with cyanoacrylate tissue glue.  We reviewed the medical records of 3 patients who 
underwent augmented trabeculectomy with MMC with early bleb leak between January 2009 and 
June 2010. All patients gave informed consent and their anonymity was preserved. 
Two cases had bleb leakage at day 1 postoperative, and one case had detected bleb leakage at 
day 7 postoperative. The diagnosis of bleb leaks was confirmed by a positive Seidel’s test, which 
also identified the leakage site. All bleb leakage was less than 2 mm size. They occurred either 
from conjunctival flap buttonhole or along suture track, which located more than 2 mm from 
limbus. The leak was complicated with low IOP of less than 10 mmHg, shallow anterior chamber 
depth but without iridocorneal touch. Other complications  such as choroidal detachment, 
hypotony maculopathy or endophthalmitis were absent in all cases. The patients retained their 
preoperative visual acuity.  
An individualised approach was used in every case. The first line of management was 
conservative which consisted of pressure padding, bandaged contact lens, and aqueous 
suppression. In first case, CATG was used along with plastic disc after 2 days failed pressure 
bandage. In second case, CATG was used alone after 2 days failed conservative method and 
subsequent surgical procedure. While in third case, CATG was used in combination with surgical 
procedure after 2 days failed pressure bandage. Summary of cases and outcome was shown in 
Table 1. 
All patients underwent application of CATG under topical anesthesia of proparacaine 0.5% or 
subconjunctiva lignocaine 2%. To facilitate instillation of CATG, 0.1 ml of CATG was filled in 1 ml 
tuberculin syringe mounted with 30 G needle. A drop of CATG was approximately equivalent to 
0.05 ml. Plastic disc was used in one of the cases (case 1). It was a modified disc of 4 mm 
diameter, cut from sterile soft clear plastic cover of butterfly needle, using straight scissors. The 
leakage sites were dried using dry cotton applicator. 
Post-gluing, they received topical eyedrops of prednisolone acetate 1% 4 hourly per day, 
ciprofoxacin 2 hourly per day, and homatropine 1% twice daily for 2 weeks. At 2 weeks, both 
prednisilone acetate 1% and ciprofloxacin were tapered to four times per day for another 2 
weeks while homatropine was stopped. At 4 weeks, ciprofloxacin was stopped and prednisolone 
acetate 1% was used four times daily for further 2 to 3 months. Patients were followed-up weekly 
after gluing for 1 month, then subsequent monthly review. During clinic visits, blebs were 
diffusely formed with no recurrent leak in all cases. No incidence of blebitis or endophthalmitis at 
3 months follow-up. 
 
Case 1  
A 57-year-old male with right eye neovascular glaucoma secondary to branch retinal vein 
occlusion underwent right eye augmented trabeculectomy. He developed filtering bleb leak on 
day 1 postoperative period. On ocular examination, there was presence of shallow bleb with 
positive Seidel test was seen at nasal part of the bleb. The anterior chamber was shallow and 
intraocular pressure (IOP) with applanation tonometry was 8 mmHg. The eye was managed with 
pressure padding and bandaged contact lens for 2 days.  Examination on following day revealed 
persistent slow bleb leak from similar site (Figure 1). Sealing of the leaking bleb with CATG with 
plastic disc was done at postoperative day 3 under slit lamp. Patient was first seated, and then 
the identified bleb leakage site was dried. One drop of CATG was applied (Figure 2), and a 
plastic disc was placed on top (Figure 3). It was allowed to crystallize for 5 minutes. The site was 
again checked with fluorescein sodium strip, and no sign of leakage was observed (Figure 4). 
Eye examination on day 1 post-gluing showed negative Seidel test, clear cornea, anterior 
chamber deepened with IOP 18 mmHg. He complained of mild foreign body sensation post-
gluing. Two weeks later the plastic disc glue was self-dislodged with no subsequent ocular 
complication. Follow up at 3 months showed well sealed bleb, no recurrent leak with IOP of 19 
mmHg. 
 
Case 2  
A 63-year-old male underwent left eye augmented trabeculectomy surgery in January 2009 for 
refractory secondary glaucoma after failed initial non-augmented trabeculectomy. He developed 
filtering bleb leak on day 1 postoperative period. On ocular examination, there was presence of 
shallow bleb with positive Seidel test was seen at temporal part of bleb. The anterior chamber 
was shallow and IOP with applanation tonometry was 6 mmHg. The eye was managed with 
pressure padding and aqueous suppression. The next day, there was persistent leaking. 
Conjunctival flap resuturing was performed. On day 3 postoperative, the bleb showed leakage 
again from the similar site with IOP 7 mmHg. Sealing of the leaking bleb with CATG was done on 
the same day. As the patient was laid supine, an eye speculum was placed to prevent blinking. 
The identified leakage site was then dried. One drop of CATG applied, and left to crystallize for 5 
minutes. The glued site was checked with fluorescein strip, and no sign of leakage observed. 
Eye examination on day 1 post-gluing revealed negative Seidel test, clear cornea, and anterior 
chamber deepened with IOP 12 mmHg. He complained of mild foreign body sensation for 
subsequent 1 week, which was tolerable with minimal irritation. The last follow up was at 3 
months post procedure whereby the filtering bleb was Siedels’ negative and IOP maintained 
below 15 mmHg. Patient was then defaulted to follow up. 
 
Case 3  
An 81-year-old female, a case of both eyes advanced primary open angle glaucoma underwent 
left eye augmented trabeculectomy in March 2009. She developed filtering bleb leak on day 7 
postoperative period. On ocular examination, there was presence of bleb leak with positive 
Seidel test near the limbus. The anterior chamber was shallow and IOP with applanation 
tonometry was undetectable. The eye was managed with pressure padding for 2 days.  
Examination on following day revealed persistent slow bleb leak from similar site. As the bleb 
was persistently leaked, she underwent combined techniques of resuturing and applying CATG 
at postoperative day 10. In supine position, eye speculum was placed. The identified leakage site 
of conjunctival flap was first resutured. The site was then dried. One drop of CATG was applied, 
and it was left to crystallize for 5 minutes. The sutured and glued site was checked with 
fluorescein strip, and there was no sign of leakage observed. Eye examination on day 1 post-
gluing noted Seidel test was negative, cornea was clear, anterior chamber deepened with IOP 10 
mmHg. There was complaint of mild foreign body sensation post-gluing for 3 weeks, however no 
severe irritation noted. At 3 months follow up, the bleb remained Siedel’s negative with the IOP 
slightly increased to 15 mmHg. 
 
 
Discussion 
Managing the bleb leaks often set a challenge upon failing both conservative approach and 
surgical repair. The incidence of postoperative bleb leakage after trabeculectomy was reported to 
reach up to 56%,10 in which higher risk was anticipated with the use of augmenting metabolites.11 
The widely use of MMC as adjunctive during trabeculectomy was found to be a cause for 
delayed bleb leaks.12 Meanwhile, early bleb leaks which comprise of wound leak and conjunctiva 
buttonholes are likely to be contributed by fluctuation changes in tissue swelling during 
postoperative period, cutting through of sutures or changes in wound apposition caused by 
blinking or eye rubbing; apart from deficient wound closure, patent stitch tracts and surgically 
traumatized conjunctiva.13   
 
Despite that, early bleb leak is not a poor prognostic indicator for intermediate bleb survival and 
IOP control in patients undergoing MMC trabeculectomy as proved by Alwitry and his team.1 
Longer follow-up of more than 1 year is necessary to futher determine relationship between early 
bleb leak and long term bleb survival. 
 
Cyanoacrylate use in managing bleb leaks and the glue has the advantage of biocompatibility 
that allows application over ocular surface with minimal toxicity while promoting and facilitating 
rapid re-epithelialization.14 Successful closure of leaking blebs with cyanoacrylate adhesive in 
studied cases were achieved either using the glue alone or in combination with other 
conservative methods, such as pressure patching, bandage soft contact lens, Simmon’s shell, 
aqeous suppressant, autologous blood, and dye-enhanced argon laser photocoagulation.15-17 
Several applications of the tissue adhesives though, may be required to ensure favorable 
outcome, as reported by Okabe and his colleagues.18 However, unsuccessful result also being 
reported with the tissue glue. Mandal attempted cyanoacrylate in 4 out of 7 cases with late bleb 
leak but found them unsuccessful.19 
 
There were significant differences between their studies and our study. Most of the previous 
reported bleb leaks were late-onset occurrence, and majority did not specify the size of the leak. 
In our cases, all three were detected very early within a week post-trabeculectomy, which was 
augmented with MMC. This is in agreement with the study conducted by Alwitry and his team, 
which found that the time of detection of early bleb leak range 1 to 21 days in MMC 
trabeculectomy patients.1 The size of leak was small in all of our cases, permitting the use of 
CATG.  
 
There was no impending vision-threatening complication set in upon the onset. We considered 
premature intervention without hypotony maculopathy or choroidal detachment was reasonable 
after adequate trial of conservative postoperative care having been undertaken. Cyanoacrylate 
adhesive was not our first line of bleb leak management though. The glue was attempted after 
failed initial conservative and/or surgical method in all of our cases.  From our 3 cases, it seemed 
that the CATG was responsible in sealing the bleb leaks. However, we admitted that we were not 
too certain that the glue alone contributed to the effective seal of the bleb leaks as many of early 
leaks seal spontaneously. In more complicated of case 3 where gluing was undertaken but in 
combination with resuturing, again the success cannot be attributed solely to the glue. 
 
From comparison of literature review and our cases, we observed that CATG could effectively be 
used as adjunct, rather than primary treatment to seal an early bleb leak of size 2 mm or less. 
CATG is not apparently suitable for thin avascular bleb with late-developing leaks. Case 
summaries of literature review were illustrated in Table 2. 
 
The advantages of CATG in the management of early bleb leakage in our cases are as follows: 
(1) clinically no toxic effect on vascular tissue (2) strong and rapid bonding (3) good adherence to 
conjunctiva (4) ability to bond in the presence of small amount of blood and tears (5) possible 
bacteriotoxicity (6) water tight, sutureless closure (7) accessible, affordable, fast, safe, simple 
and relatively ease of application.  
 
There are few insignificant limitations over its use that have been addressed: (1) big pre-
sterilized glue container tip making it difficult to specify and localize to the desired site (2) too 
liquify properties causing it to diffuse to other undesired surrounding site while waiting it to 
solidify (3) forming solid, impermeable mass in situ which persist as a foreign body, thus giving 
rise to foreign body sensation (4) impermeable to fluids and metabolites (5) risk of development 
of severe peri-bleb inflammation around both the glue and the plastic disc in the weeks after 
gluing, before the glue ultimately naturally dislodges. 
 
Conclusion  
CATG may serve as one of the effective alternative adjunctive method in the management of 
post-trabeculectomy early bleb leak. Nevertheless, further study of its use in various phases of 
bleb leak is required. Modification of product preparation of CATG for ophthalmic use will 
facilitate the usage.  
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Table 1: Summary of cases and outcome 
 
 
Case 
 
Age, 
Gender,  
Type of 
Glaucoma 
 
Onset of 
bleb leak  
 
Initial failed 
methods 
 
Application method of CATG 
Time of treatment 
 
IOP during bleb 
leak (mmHg) 
 
IOP post 
gluing 
(mmHg) 
 
 
Outcome 
 
 
1 
 
57 y/o, M , 
NVG 
 
Post op  
Day 1 
 
Pressure padding 
Bandage contact lens 
 
CATG with plastic disc 
 Post op Day 3 
 
 
8 
 
18 
 
Success 
2 63 y/o, M, 
NVG 
Post op  
Day 1 
Pressure padding 
Aqueous suppression 
Resuturing 
 
CATG alone 
 Post Op Day 3 
 
7 12 Success 
3 81 y/o, F, 
POAG 
Post op  
Day 7 
Pressure padding CATG with resuturing  
Post op Day 10 
 
undetectable 10 Success 
 
Abbreviation: M, Male; F, Female; CATG, cyanoacrylate tissue glue; NVG, neovascular 
glaucoma; POAG, primary open angle glaucoma; IOP, intraocular pressure; op, operation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Case summaries of literature review  
 
 
 
 
 
Author 
 
 
 
Total 
 
 
 
Onset of 
bleb leak 
 
Management of bleb leak 
 
Complications 
observed 
 
CATG alone 
 
Combine CATG 
& other methods 
 
Other 
methods 
  
Total 
 
Success 
 
Fail 
 
Total 
 
Success 
 
Fail 
 
Total 
 
 
Zalta & Wieder15  
 
5* 
 
10 month 
– 20  year 
 
1 
 
1 
 
0 
 
4 
 
4 
 
0 
 
- 
 
corneal abrasion 
 
 
Wilensky16 
 
12* 
 
6 month 
– 20 year  
 
- 
 
- 
 
- 
 
2 
 
2 
 
0 
 
10α 
 
N/A 
 
 
Euswas et al17  7* Late onset 
 
- - - 2 2 0 5α N/A 
 
Okabe et al18 2* Late onset 
 
- - - 2 2 0 - N/A 
 
Mandal19 7* 1.5 year  
– 16 year 
- - - 4 0 4 7α N/A 
 
 
Our series 3* < 2 week 1 1 0 2 2 0 - foreign body 
sensation 
 
*cases managed with glue were included, αother methods of management of bleb leak also included, N/A – not available 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure legend 
Figure 1: Leaking bleb with Siedel’s test positive (arrow) in case 1. 
Figure 2: Application of cyanoacrylate tissue glue (arrow) in case 1. 
Figure 3: Plastic disc applied on top of cyanoacrylate tissue glue (arrow) case 1. 
Figure 4: Sealed leaking bleb with Siedel’s negative. Plastic disc in situ (arrow) surrounded by 
crystalized cyanoacrylate tissue glue in case 1. 
 
 
 
 
 
  
  
 
